Currently	currently	RB	O
,	,	,	O
the	the	DT	O
main	main	JJ	O
cause	cause	NN	O
of	of	IN	O
dementia	dementia	NN	O
in	in	IN	O
the	the	DT	O
elderly	elderly	JJ	O
is	be	VBZ	O
Alzheimer	Alzheimer	NNP	O
’s	’s	POS	O
disease	disease	NN	O
AD	ad	NN	O
,	,	,	O
which	which	WDT	O
can	can	MD	O
impair	impair	VB	O
cognitive	cognitive	JJ	O
and	and	CC	O
memory	memory	NN	O
aspects	aspect	NNS	O
.	.	.	O

AD	ad	NN	O
is	be	VBZ	O
responsible	responsible	JJ	O
for	for	IN	O
about	about	RB	O
60–80	60–80	CD	O
%	%	NN	O
of	of	IN	O
all	all	DT	O
dementia	dementia	NN	O
types	type	NNS	O
in	in	IN	O
the	the	DT	O
elderly	elderly	JJ	O
and	and	CC	O
is	be	VBZ	O
considered	consider	VBN	O
to	to	TO	O
be	be	VB	O
a	a	DT	O
progressive	progressive	JJ	O
and	and	CC	O
irreversible	irreversible	JJ	O
neurodegenerative	neurodegenerative	JJ	O
diseaseCYTOWANIE	diseasecytowanie	NN	O
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
estimated	estimate	VBN	O
that	that	IN	O
in	in	IN	O
2015	2015	CD	O
more	more	JJR	O
than	than	IN	O
46.8	46.8	CD	O
million	million	CD	O
people	people	NNS	O
worldwide	worldwide	RB	O
had	have	VBD	O
dementia	dementia	NN	O
and	and	CC	O
this	this	DT	O
number	number	NN	O
is	be	VBZ	O
expected	expect	VBN	O
to	to	TO	O
double	double	VB	O
every	every	DT	O
20	20	CD	O
 	 	_SP	O
years	year	NNS	O
reaching	reach	VBG	O
almost	almost	RB	O
131.5	131.5	CD	O
million	million	CD	O
in	in	IN	O
2050CYTOWANIE	2050cytowanie	CD	O
.	.	.	O

The	the	DT	O
etiopathogenesis	etiopathogenesis	NN	O
of	of	IN	O
AD	AD	NNP	O
still	still	RB	O
remains	remain	VBZ	O
unknown	unknown	JJ	O
although	although	IN	O
but	but	CC	O
several	several	JJ	O
involved	involved	JJ	O
factors	factor	NNS	O
have	have	VBP	O
been	be	VBN	O
identified	identify	VBN	O
and	and	CC	O
found	find	VBD	O
consistent	consistent	JJ	O
with	with	IN	O
its	-PRON-	PRP$	O
onset	onset	NN	O
.	.	.	O

Among	among	IN	O
them	-PRON-	PRP	O
is	be	VBZ	O
the	the	DT	O
impairment	impairment	NN	O
of	of	IN	O
cholinergic	cholinergic	JJ	O
system	system	NN	O
,	,	,	O
as	as	IN	O
indicated	indicate	VBN	O
by	by	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
altered	alter	VBN	O
cholinergic	cholinergic	JJ	O
markers	marker	NNS	O
in	in	IN	O
AD	ad	NN	O
patients	patient	NNS	O
.	.	.	O

This	this	DT	O
results	result	VBZ	O
in	in	IN	O
a	a	DT	O
pronounced	pronounced	JJ	O
acetylcholine	acetylcholine	NN	O
ACh	ACh	NNP	O
deficiency	deficiency	NN	O
which	which	WDT	O
translates	translate	VBZ	O
into	into	IN	O
a	a	DT	O
generalised	generalise	VBN	O
withdrawal	withdrawal	NN	O
of	of	IN	O
cholinergic	cholinergic	NN	O
toneCYTOWANIE	toneCYTOWANIE	NNP	O
.	.	.	O

ACh	ACh	NNP	O
is	be	VBZ	O
a	a	DT	O
cholinergic	cholinergic	JJ	O
neurotransmitter	neurotransmitter	NN	O
,	,	,	O
which	which	WDT	O
may	may	MD	O
exert	exert	VB	O
its	-PRON-	PRP$	O
effects	effect	NNS	O
via	via	IN	O
muscarinic	muscarinic	JJ	O
and	and	CC	O
nicotinic	nicotinic	JJ	O
receptors	receptor	NNS	O
found	find	VBD	O
throughout	throughout	IN	O
the	the	DT	O
central	central	JJ	O
nervous	nervous	JJ	O
system	system	NN	O
.	.	.	O

However	however	RB	O
,	,	,	O
once	once	RB	O
in	in	IN	O
the	the	DT	O
synaptic	synaptic	JJ	O
cleft	cleft	NN	O
,	,	,	O
the	the	DT	O
ACh	ACh	NNPS	O
can	can	MD	O
still	still	RB	O
be	be	VB	O
hydrolysed	hydrolyse	VBN	O
in	in	IN	O
a	a	DT	O
reaction	reaction	NN	O
catalysed	catalyse	VBN	O
by	by	IN	O
the	the	DT	O
enzyme	enzyme	NNS	O
acetylcholinesterase	acetylcholinesterase	NN	O
AChE	ache	NN	O
,	,	,	O
giving	give	VBG	O
rise	rise	NN	O
to	to	IN	O
acetate	acetate	NN	O
and	and	CC	O
choline	choline	VB	O
,	,	,	O
thus	thus	RB	O
interrupting	interrupt	VBG	O
the	the	DT	O
signalling	signalling	NN	O
mediated	mediate	VBN	O
by	by	IN	O
ACh	ACh	NNS	O
.	.	.	O

The	the	DT	O
progressive	progressive	JJ	O
loss	loss	NN	O
of	of	IN	O
cholinergic	cholinergic	JJ	O
neurons	neuron	NNS	O
contribute	contribute	VBP	O
significantly	significantly	RB	O
to	to	IN	O
the	the	DT	O
memory	memory	NN	O
and	and	CC	O
attention	attention	NN	O
deficits	deficit	NNS	O
found	find	VBN	O
in	in	IN	O
ADCYTOWANIE	ADCYTOWANIE	NNP	O
.	.	.	O

Although	although	IN	O
the	the	DT	O
exact	exact	JJ	O
mechanisms	mechanism	NNS	O
involved	involve	VBN	O
in	in	IN	O
the	the	DT	O
pathogenesis	pathogenesis	NN	O
of	of	IN	O
AD	ad	NN	O
are	be	VBP	O
not	not	RB	O
yet	yet	RB	O
known	know	VBN	O
,	,	,	O
the	the	DT	O
findings	finding	NNS	O
on	on	IN	O
the	the	DT	O
subject	subject	NN	O
in	in	IN	O
the	the	DT	O
last	last	JJ	O
decades	decade	NNS	O
encourage	encourage	VBP	O
the	the	DT	O
search	search	NN	O
for	for	IN	O
new	new	JJ	O
pharmacological	pharmacological	JJ	O
therapies	therapy	NNS	O
more	more	RBR	O
effective	effective	JJ	O
and	and	CC	O
with	with	IN	O
fewer	few	JJR	O
side	side	NN	O
effects	effect	NNS	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
research	research	NN	O
suggests	suggest	VBZ	O
that	that	IN	O
specific	specific	JJ	O
dysfunctions	dysfunction	NNS	O
in	in	IN	O
cholinergic	cholinergic	JJ	O
transmission	transmission	NN	O
may	may	MD	O
be	be	VB	O
responsible	responsible	JJ	O
for	for	IN	O
the	the	DT	O
decline	decline	NN	O
in	in	IN	O
memory	memory	NN	O
observed	observe	VBN	O
in	in	IN	O
older	old	JJR	O
peopleCYTOWANIE	peopleCYTOWANIE	NNP	O
.	.	.	O

AChE	AChE	``	O
competitive	competitive	JJ	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
widely	widely	RB	O
used	use	VBN	O
drugs	drug	NNS	O
to	to	TO	O
treat	treat	VB	O
AD	ad	NN	O
patients	patient	NNS	O
.	.	.	O

AChE	AChE	``	O
inhibitors	inhibitor	NNS	O
can	can	MD	O
produce	produce	VB	O
promising	promising	JJ	O
results	result	NNS	O
increasing	increase	VBG	O
ACh	ach	JJ	O
levels	level	NNS	O
in	in	IN	O
the	the	DT	O
synaptic	synaptic	JJ	O
cleft	cleft	NNS	O
and	and	CC	O
partially	partially	RB	O
ameliorate	ameliorate	VB	O
cognitive	cognitive	JJ	O
symptoms	symptom	NNS	O
,	,	,	O
enhancing	enhance	VBG	O
the	the	DT	O
quality	quality	NN	O
of	of	IN	O
life	life	NN	O
and	and	CC	O
diminish	diminish	JJ	O
caregiver	caregiver	NN	O
burden	burden	NN	O
for	for	IN	O
patients	patient	NNS	O
with	with	IN	O
ADCYTOWANIE	ADCYTOWANIE	NNP	O
.	.	.	O

There	there	EX	O
are	be	VBP	O
currently	currently	RB	O
four	four	CD	O
drugs	drug	NNS	O
approved	approve	VBN	O
treatments	treatment	NNS	O
by	by	IN	O
US	US	NNP	O
Food	Food	NNP	O
and	and	CC	O
Drug	Drug	NNP	O
Administration	Administration	NNP	O
that	that	DT	O
act	act	VBP	O
as	as	IN	O
an	an	DT	O
AChE	AChE	``	O
inhibitor	inhibitor	NN	O
and	and	CC	O
that	that	WDT	O
are	be	VBP	O
used	use	VBN	O
to	to	TO	O
treat	treat	VB	O
the	the	DT	O
cognitive	cognitive	JJ	O
manifestations	manifestation	NNS	O
of	of	IN	O
AD	ad	NN	O
:	:	:	O
rivastigmine	rivastigmine	NN	O
Exelon	Exelon	NNP	O
,	,	,	O
galantamine	galantamine	NN	O
Razadyne	Razadyne	NNP	O
,	,	,	O
Reminyl	Reminyl	NNP	O
,	,	,	O
tacrine	tacrine	JJ	O
Cognex	Cognex	NNP	O
and	and	CC	O
donepezil	donepezil	NNP	O
Aricept)CYTOWANIE	aricept)cytowanie	CD	O
,	,	,	B
.	.	.	O

Tacrine	Tacrine	NNP	O
was	be	VBD	O
the	the	DT	O
first	first	JJ	O
approved	approve	VBN	O
potent	potent	JJ	O
and	and	CC	O
clinically	clinically	RB	O
effective	effective	JJ	O
AChE	AChE	''	O
inhibitor	inhibitor	NN	O
in	in	IN	O
1993	1993	CD	O
and	and	CC	O
was	be	VBD	O
withdrawn	withdraw	VBN	O
from	from	IN	O
the	the	DT	O
pharmaceutical	pharmaceutical	JJ	O
market	market	NN	O
in	in	IN	O
1998	1998	CD	O
due	due	IN	O
to	to	IN	O
hepatotoxicityCYTOWANIE	hepatotoxicityCYTOWANIE	NNP	O
.	.	.	O

In	in	IN	O
general	general	JJ	O
,	,	,	O
galantamine	galantamine	NN	O
,	,	,	O
rivastigmine	rivastigmine	NN	O
and	and	CC	O
donezepil	donezepil	NN	O
are	be	VBP	O
most	most	RBS	O
effective	effective	JJ	O
when	when	WRB	O
treatment	treatment	NN	O
is	be	VBZ	O
initiated	initiate	VBN	O
in	in	IN	O
the	the	DT	O
early	early	JJ	O
stages	stage	NNS	O
of	of	IN	O
disease	disease	NN	O
.	.	.	O

Rivastigmine	rivastigmine	NN	O
is	be	VBZ	O
able	able	JJ	O
to	to	TO	O
block	block	VB	O
butyrylcholinesterase	butyrylcholinesterase	NN	O
,	,	,	O
while	while	IN	O
galantamine	galantamine	NN	O
modulates	modulate	VBZ	O
nicotinic	nicotinic	JJ	O
acetylcholine	acetylcholine	NN	O
receptors	receptor	NNS	O
.	.	.	O

On	on	IN	O
the	the	DT	O
other	other	JJ	O
hand	hand	NN	O
,	,	,	O
donepezil	donepezil	JJ	O
prevents	prevent	VBZ	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
Aβ	Aβ	NNP	O
through	through	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
Aβ	Aβ	NNP	O
self	self	NN	O
-	-	HYPH	O
aggregation	aggregation	NN	O
and	and	CC	O
β	β	NNP	O
-	-	HYPH	O
secretase	secretase	NNP	O
,	,	,	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
being	be	VBG	O
able	able	JJ	O
to	to	TO	O
interact	interact	VB	O
with	with	IN	O
the	the	DT	O
sigma-1	sigma-1	NNP	O
receptors	receptor	NNS	O
,	,	,	O
which	which	WDT	O
have	have	VBP	O
anti	anti	JJ	O
-	-	JJ	O
amnesic	amnesic	JJ	O
functionCYTOWANIE	functionCYTOWANIE	NNP	O
,	,	,	B
.	.	.	O

Although	although	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
AChE	AChE	``	O
is	be	VBZ	O
a	a	DT	O
widely	widely	RB	O
used	use	VBN	O
therapeutic	therapeutic	JJ	O
approach	approach	NN	O
for	for	IN	O
AD	ad	NN	O
,	,	,	O
this	this	DT	O
strategy	strategy	NN	O
only	only	RB	O
softens	soften	VBZ	O
the	the	DT	O
symptoms	symptom	NNS	O
of	of	IN	O
this	this	DT	O
disease	disease	NN	O
and	and	CC	O
is	be	VBZ	O
,	,	,	O
therefore	therefore	RB	O
,	,	,	O
a	a	DT	O
palliative	palliative	JJ	O
treatment	treatment	NN	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
AChE	AChE	``	O
inhibitors	inhibitor	NNS	O
have	have	VBP	O
extensive	extensive	JJ	O
side	side	NN	O
effects	effect	NNS	O
and	and	CC	O
limited	limited	JJ	O
beneficial	beneficial	JJ	O
effectsCYTOWANIE	effectsCYTOWANIE	NNP	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
several	several	JJ	O
studies	study	NNS	O
have	have	VBP	O
focussed	focusse	VBN	O
on	on	IN	O
the	the	DT	O
search	search	NN	O
for	for	IN	O
more	more	JJR	O
effective	effective	JJ	O
therapies	therapy	NNS	O
and	and	CC	O
with	with	IN	O
fewer	few	JJR	O
adverse	adverse	JJ	O
effects	effect	NNS	O
for	for	IN	O
AD	ad	NN	O
.	.	.	O

In	in	IN	O
this	this	DT	O
sense	sense	NN	O
,	,	,	O
medicinal	medicinal	JJ	O
chemistry	chemistry	NN	O
has	have	VBZ	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
to	to	TO	O
design	design	NN	O
,	,	,	O
synthesise	synthesise	VB	O
and	and	CC	O
develop	develop	VB	O
new	new	JJ	O
molecules	molecule	NNS	O
with	with	IN	O
biological	biological	JJ	O
activity	activity	NN	O
through	through	IN	O
the	the	DT	O
use	use	NN	O
of	of	IN	O
different	different	JJ	O
strategies	strategy	NNS	O
of	of	IN	O
detection	detection	NN	O
for	for	IN	O
possible	possible	JJ	O
drugsCYTOWANIE	drugscytowanie	NN	O
.	.	.	O

Heterocyclic	heterocyclic	JJ	O
compounds	compound	NNS	O
,	,	,	O
with	with	IN	O
nitrogen	nitrogen	NN	O
and	and	CC	O
sulphur	sulphur	NN	O
atoms	atom	NNS	O
and	and	CC	O
five	five	CD	O
-	-	HYPH	O
member	member	NN	O
and	and	CC	O
six	six	CD	O
-	-	HYPH	O
member	member	NN	O
rings	ring	NNS	O
,	,	,	O
are	be	VBP	O
of	of	IN	O
great	great	JJ	O
interest	interest	NN	O
in	in	IN	O
the	the	DT	O
field	field	NN	O
of	of	IN	O
synthetic	synthetic	JJ	O
organic	organic	JJ	O
chemistry	chemistry	NN	O
and	and	CC	O
medicinal	medicinal	JJ	O
chemistryCYTOWANIE	chemistryCYTOWANIE	NNP	O
,	,	,	B
.	.	.	O

Thiazolidinone	thiazolidinone	DT	O
belongs	belong	VBZ	O
to	to	IN	O
this	this	DT	O
class	class	NN	O
and	and	CC	O
is	be	VBZ	O
a	a	DT	O
versatile	versatile	JJ	O
scaffold	scaffold	NN	O
to	to	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
new	new	JJ	O
bioactive	bioactive	JJ	O
compounds	compound	NNS	O
.	.	.	O

Numerous	numerous	JJ	O
studies	study	NNS	O
describe	describe	VBP	O
a	a	DT	O
wide	wide	JJ	O
range	range	NN	O
of	of	IN	O
pharmacological	pharmacological	JJ	O
properties	property	NNS	O
of	of	IN	O
thiazolidinones	thiazolidinone	NNS	O
:	:	:	O
anti	anti	NNP	O
-	-	NNP	O
HIVCYTOWANIE	HIVCYTOWANIE	NNP	O
,	,	,	O
antitumorCYTOWANIE	antitumorCYTOWANIE	NNP	O
,	,	,	B
,	,	,	O
anti	anti	NNS	O
-	-	NNP	O
inflammatoryCYTOWANIE	inflammatoryCYTOWANIE	NNP	O
,	,	,	O
antimicrobialCYTOWANIE	antimicrobialCYTOWANIE	NNP	O
,	,	,	O
antihyperglycemicCYTOWANIE	antihyperglycemicCYTOWANIE	NNP	O
,	,	,	O
and	and	CC	O
acetyl	acetyl	NNP	O
/	/	SYM	O
butyrylcholinesterase	butyrylcholinesterase	NNP	O
inhibitionCYTOWANIE	inhibitionCYTOWANIE	NNP	O
.	.	.	O

Thiazinanones	Thiazinanones	NNP	O
six	six	CD	O
-	-	HYPH	O
membered	membere	VBN	O
heterocycle	heterocycle	NN	O
also	also	RB	O
show	show	VBP	O
important	important	JJ	O
biological	biological	JJ	O
activity	activity	NN	O
such	such	JJ	O
as	as	IN	O
anticancerCYTOWANIE	anticancerCYTOWANIE	NNP	O
,	,	,	O
antimalarialCYTOWANIE	antimalarialCYTOWANIE	NNP	O
,	,	,	O
antihypertensiveCYTOWANIE	antihypertensiveCYTOWANIE	NNP	O
,	,	,	O
antibacterialCYTOWANIE	antibacterialCYTOWANIE	NNP	O
,	,	,	O
and	and	CC	O
antihyperglycemicCYTOWANIE	antihyperglycemiccytowanie	FW	O
.	.	.	O

Both	both	DT	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNPS	O
have	have	VBP	O
similar	similar	JJ	O
syntheses	synthesis	NNS	O
strategy	strategy	NN	O
.	.	.	O

The	the	DT	O
main	main	JJ	O
synthetic	synthetic	JJ	O
route	route	NN	O
involves	involve	VBZ	O
three	three	CD	O
components	component	NNS	O
an	an	DT	O
aldehyde	aldehyde	NN	O
or	or	CC	O
ketone	ketone	NN	O
,	,	,	O
a	a	DT	O
primary	primary	JJ	O
amine	amine	NN	O
,	,	,	O
and	and	CC	O
carboxylic	carboxylic	JJ	O
acid	acid	NN	O
.	.	.	O

The	the	DT	O
reactions	reaction	NNS	O
proceed	proceed	VBP	O
by	by	IN	O
initial	initial	JJ	O
formation	formation	NN	O
of	of	IN	O
an	an	DT	O
imine	imine	NN	O
followed	follow	VBN	O
by	by	IN	O
intramolecular	intramolecular	JJ	O
cyclisation	cyclisation	NN	O
and	and	CC	O
elimination	elimination	NN	O
of	of	IN	O
water	water	NN	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
these	these	DT	O
methods	method	NNS	O
can	can	MD	O
be	be	VB	O
applied	apply	VBN	O
in	in	IN	O
two	two	CD	O
-	-	HYPH	O
steps	step	NNS	O
,	,	,	O
one	one	CD	O
step	step	NN	O
multicomponent	multicomponent	NN	O
all	all	DT	O
reactants	reactant	NNS	O
together	together	RB	O
at	at	IN	O
the	the	DT	O
beginning	beginning	NN	O
of	of	IN	O
reaction	reaction	NN	O
or	or	CC	O
one	one	CD	O
-	-	HYPH	O
step	step	NN	O
one	one	CD	O
-	-	HYPH	O
pot	pot	NN	O
reactions	reaction	NNS	O
,	,	,	O
under	under	IN	O
catalysis	catalysis	NN	O
or	or	CC	O
notCYTOWANIE	notcytowanie	ADD	O
.	.	.	O

We	-PRON-	PRP	O
have	have	VBP	O
been	be	VBN	O
studying	study	VBG	O
these	these	DT	O
classes	class	NNS	O
of	of	IN	O
heterocycles	heterocycle	NNS	O
in	in	IN	O
a	a	DT	O
few	few	JJ	O
yearsCYTOWANIE	yearscytowanie	NN	O
and	and	CC	O
in	in	IN	O
continuation	continuation	NN	O
of	of	IN	O
our	-PRON-	PRP$	O
research	research	NN	O
programme	programme	NN	O
,	,	,	O
this	this	DT	O
work	work	NN	O
aims	aim	VBZ	O
to	to	TO	O
synthesise	synthesise	VB	O
novel	novel	JJ	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNPS	O
from	from	IN	O
a	a	DT	O
specific	specific	JJ	O
amine	amine	NN	O
,	,	,	O
the	the	DT	O
1–(2-aminoethyl)pyrrolidine	1–(2-aminoethyl)pyrrolidine	CD	O
,	,	,	O
affording	afford	VBG	O
compounds	compound	NNS	O
structurally	structurally	RB	O
similar	similar	JJ	O
to	to	IN	O
AChE	AChE	``	O
that	that	WDT	O
could	could	MD	O
act	act	VB	O
as	as	IN	O
AChE	AChE	``	O
inhibitors	inhibitor	NNS	O
Figure	figure	NN	O
1	1	CD	O
.	.	.	O

The	the	DT	O
same	same	JJ	O
strategy	strategy	NN	O
was	be	VBD	O
used	use	VBN	O
in	in	IN	O
previous	previous	JJ	O
work	work	NN	O
with	with	IN	O
good	good	JJ	O
resultsCYTOWANIE	resultsCYTOWANIE	NNP	O
.	.	.	O

Another	another	DT	O
goal	goal	NN	O
is	be	VBZ	O
the	the	DT	O
AChE	AChE	``	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
and	and	CC	O
cytotoxicity	cytotoxicity	NN	O
of	of	IN	O
synthesised	synthesise	VBN	O
compounds	compound	NNS	O
,	,	,	O
contributing	contribute	VBG	O
to	to	IN	O
the	the	DT	O
search	search	NN	O
for	for	IN	O
new	new	JJ	O
compounds	compound	NNS	O
that	that	WDT	O
can	can	MD	O
be	be	VB	O
used	use	VBN	O
for	for	IN	O
the	the	DT	O
AD	ad	NN	O
treatment	treatment	NN	O
.	.	.	O

Similarity	similarity	NN	O
at	at	IN	O
chemical	chemical	NN	O
structure	structure	NN	O
of	of	IN	O
acetylcholine	acetylcholine	NN	O
,	,	,	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
5	5	CD	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-one	NNS	O
6	6	CD	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
solvents	solvent	NNS	O
were	be	VBD	O
used	use	VBN	O
as	as	IN	O
obtained	obtain	VBN	O
from	from	IN	O
commercial	commercial	JJ	O
suppliers	supplier	NNS	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
.	.	.	O

The	the	DT	O
melting	melt	VBG	O
points	point	NNS	O
were	be	VBD	O
determined	determine	VBN	O
on	on	IN	O
a	a	DT	O
Fisatom	Fisatom	NNP	O
brand	brand	NN	O
machine	machine	NN	O
with	with	IN	O
three	three	CD	O
capillary	capillary	JJ	O
tubes	tube	NNS	O
,	,	,	O
model	model	NN	O
430	430	CD	O
,	,	,	O
230	230	CD	O
 	 	_SP	O
V	v	NN	O
,	,	,	O
60	60	CD	O
 	 	_SP	O
Hz	Hz	NNP	O
,	,	,	O
50	50	CD	O
 	 	_SP	O
W.	W.	NNP	O
Thermometer	Thermometer	NNP	O
was	be	VBD	O
set	set	VBN	O
up	up	RP	O
to	to	IN	O
360	360	CD	O
 	 	_SP	O
°	°	,	O
C	C	NNP	O
.	.	.	O

The	the	DT	O
characterisation	characterisation	NN	O
of	of	IN	O
the	the	DT	O
molecules	molecule	NNS	O
was	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
Gas	Gas	NNP	O
Chromatograph	Chromatograph	NNP	O
coupled	couple	VBD	O
Mass	Mass	NNP	O
Spectra	Spectra	NNP	O
GC	GC	NNP	O
/	/	SYM	O
MS	MS	NNP	O
and	and	CC	O
1H	1h	CD	O
,	,	,	O
13	13	CD	O
 	 	_SP	O
C	c	NN	O
and	and	CC	O
2	2	CD	O
 	 	_SP	O
D	D	NNP	O
nuclear	nuclear	JJ	O
magnetic	magnetic	JJ	O
resonance	resonance	NN	O
spectroscopy	spectroscopy	NN	O
NMR	NMR	NNP	O
.	.	.	O

The	the	DT	O
mass	mass	JJ	O
spectra	spectra	NN	O
were	be	VBD	O
obtained	obtain	VBN	O
on	on	IN	O
a	a	DT	O
Shimadzu	Shimadzu	NNP	O
GCMS	GCMS	NNP	O
-	-	:	O
QP2010SE	QP2010SE	NNP	O
with	with	IN	O
a	a	DT	O
split	split	JJ	O
-	-	HYPH	O
splitless	splitless	NN	O
injector	injector	NN	O
and	and	CC	O
equipped	equip	VBN	O
with	with	IN	O
a	a	DT	O
RDX	RDX	NNP	O
-	-	HYPH	O
SMS	sms	NN	O
capillary	capillary	JJ	O
column	column	NN	O
30	30	CD	O
 	 	_SP	O
m	m	CD	O
 	 	_SP	O
×	×	NN	O
 	 	_SP	O
0.25	0.25	CD	O
 	 	_SP	O
mm	mm	NN	O
×	×	NNP	O
0.25	0.25	CD	O
 	 	_SP	O
μm	μm	NN	O
;	;	:	O
helium	helium	NN	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
the	the	DT	O
carrier	carrier	NN	O
gas	gas	NN	O
56	56	CD	O
 	 	_SP	O
kPa	kPa	NNS	O
.	.	.	O

1H	1H	NNP	O
and	and	CC	O
13	13	CD	O
 	 	_SP	O
C	C	NNP	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
a	a	DT	O
Bruker	Bruker	NNP	O
Ac-200F	Ac-200F	NNP	O
1H	1H	NNP	O
de	de	IN	O
200	200	CD	O
 	 	_SP	O
MHz	MHz	NNS	O
e	e	CC	O
13	13	CD	O
 	 	_SP	O
C	c	NN	O
de	de	IN	O
50	50	CD	O
 	 	_SP	O
MHz	MHz	NNS	O
,	,	,	O
on	on	IN	O
a	a	DT	O
Bruker	Bruker	NNP	O
Avance	Avance	NNP	O
600	600	CD	O
spectrometer	spectrometer	IN	O
1H	1h	CD	O
at	at	IN	O
600	600	CD	O
 	 	_SP	O
MHz	MHz	NNS	O
and	and	CC	O
13	13	CD	O
 	 	_SP	O
C	c	NN	O
at	at	IN	O
150	150	CD	O
 	 	_SP	O
MHz	MHz	NNS	O
,	,	,	O
in	in	IN	O
CDCl3	CDCl3	NNP	O
containing	contain	VBG	O
tetramethylsilane	tetramethylsilane	NN	O
TMS	TMS	NNP	O
as	as	IN	O
an	an	DT	O
internal	internal	JJ	O
standard	standard	NN	O
.	.	.	O

2	2	CD	O
 	 	_SP	O
D	D	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
COSY	COSY	NNP	O
,	,	,	O
HSQC	HSQC	NNP	O
and	and	CC	O
HMBC	HMBC	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
using	use	VBG	O
the	the	DT	O
Bruker	Bruker	NNP	O
Ac-200F	Ac-200F	NNP	O
250	250	CD	O
 	 	_SP	O
MHz	MHz	NNS	O
spectrophotometer	spectrophotomet	JJR	O
in	in	IN	O
chloroform	chloroform	NN	O
CDCl3	CDCl3	NNP	O
containing	contain	VBG	O
TMS	TMS	NNP	O
as	as	IN	O
an	an	DT	O
internal	internal	JJ	O
standard	standard	NN	O
.	.	.	O

Spectra	Spectra	NNP	O
processing	processing	NN	O
was	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
the	the	DT	O
FID	FID	NNP	O
file	file	NN	O
using	use	VBG	O
the	the	DT	O
Magnetic	Magnetic	NNP	O
Resonance	Resonance	NNP	O
Companion	Companion	NNP	O
NMR	NMR	NNP	O
Manager	Manager	NNP	O
MestReC	MestReC	NNP	O
,	,	,	O
MestReNOVA	mestrenova	CD	O
6.0.2	6.0.2	CD	O
-	-	HYPH	O
5475	5475	CD	O
and	and	CC	O
Advanced	Advanced	NNP	O
Chemistry	Chemistry	NNP	O
Development	Development	NNP	O
ACD	acd	CD	O
2	2	CD	O
 	 	_SP	O
D	D	NNP	O
NMR	NMR	NNP	O
Manager	Manager	NNP	O
.	.	.	O

Mass	Mass	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
for	for	IN	O
all	all	DT	O
compounds	compound	NNS	O
on	on	IN	O
an	an	DT	O
LTQ	LTQ	NNP	O
Orbitrap	Orbitrap	NNP	O
Discovery	Discovery	NNP	O
mass	mass	NN	O
spectrometer	spectrometer	NN	O
Thermo	Thermo	NNP	O
Fisher	Fisher	NNP	O
Scientific	Scientific	NNP	O
.	.	.	O

This	this	DT	O
hybrid	hybrid	JJ	O
system	system	NN	O
meets	meet	VBZ	O
the	the	DT	O
LTQ	LTQ	NNP	O
XL	XL	NNP	O
linear	linear	NN	O
ion	ion	NN	O
trap	trap	NN	O
mass	mass	NN	O
spectrometer	spectrometer	NN	O
and	and	CC	O
an	an	DT	O
Orbitrap	Orbitrap	NNP	O
mass	mass	NN	O
analyser	analyser	NN	O
.	.	.	O

The	the	DT	O
experiments	experiment	NNS	O
were	be	VBD	O
performed	perform	VBN	O
via	via	IN	O
direct	direct	JJ	O
infusion	infusion	NN	O
of	of	IN	O
sample	sample	NN	O
flow	flow	NN	O
:	:	:	O
15	15	CD	O
 	 	_SP	O
μL	μL	NNP	O
/	/	SYM	O
min	min	NNP	O
in	in	IN	O
the	the	DT	O
positive	positive	JJ	O
-	-	HYPH	O
ion	ion	NN	O
mode	mode	NN	O
using	use	VBG	O
electrospray	electrospray	JJ	O
ionisation	ionisation	NN	O
.	.	.	O

Elemental	elemental	JJ	O
composition	composition	NN	O
calculations	calculation	NNS	O
for	for	IN	O
comparison	comparison	NN	O
were	be	VBD	O
executed	execute	VBN	O
using	use	VBG	O
the	the	DT	O
specific	specific	JJ	O
tool	tool	NN	O
included	include	VBN	O
in	in	IN	O
the	the	DT	O
Qual	Qual	NNP	O
Browser	Browser	NNP	O
module	module	NN	O
of	of	IN	O
Xcalibur	Xcalibur	NNP	O
Thermo	Thermo	NNP	O
Fisher	Fisher	NNP	O
Scientific	Scientific	NNP	O
,	,	,	O
release	release	NN	O
2.0.7	2.0.7	CD	O
software	software	NN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
carried	carry	VBN	O
out	out	IN	O
of	of	IN	O
1-(2-aminoethyl)pyrrolidine	1-(2-aminoethyl)pyrrolidine	CD	O
1	1	CD	O
1	1	CD	O
 	 	_SP	O
mmol	mmol	NN	O
and	and	CC	O
arenealdehyde	arenealdehyde	NNP	O
2a	2a	CD	O
-	-	HYPH	O
x	x	NNP	O
1	1	CD	O
 	 	_SP	O
mmol	mmol	NN	O
,	,	,	O
under	under	IN	O
stirring	stirring	NN	O
,	,	,	O
reflux	reflux	NN	O
of	of	IN	O
toluene	toluene	JJ	O
70	70	CD	O
 	 	_SP	O
ml	ml	NN	O
and	and	CC	O
a	a	DT	O
Dean	Dean	NNP	O
-	-	HYPH	O
Stark	Stark	NNP	O
system	system	NN	O
for	for	IN	O
2	2	CD	O
 	 	_SP	O
h.	h.	NN	O
Thereafter	Thereafter	NNP	O
,	,	,	O
a	a	DT	O
mercaptocarboxylic	mercaptocarboxylic	JJ	O
acid	acid	NN	O
3	3	CD	O
 	 	_SP	O
mmol	mmol	NN	O
was	be	VBD	O
added	add	VBN	O
in	in	IN	O
the	the	DT	O
reaction	reaction	NN	O
.	.	.	O

The	the	DT	O
mercaptoacetic	mercaptoacetic	JJ	O
acid	acid	NN	O
4a	4a	CD	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
obtain	obtain	VB	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
5	5	CD	O
and	and	CC	O
the	the	DT	O
mercaptopropionic	mercaptopropionic	JJ	O
acid	acid	NN	O
4	4	CD	O
 	 	_SP	O
b	b	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
obtain	obtain	VB	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6	6	CD	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
maintaining	maintain	VBG	O
in	in	IN	O
reflux	reflux	NN	O
of	of	IN	O
toluene	toluene	JJ	O
for	for	IN	O
more	more	JJR	O
5	5	CD	O
 	 	_SP	O
h	h	NN	O
and	and	CC	O
then	then	RB	O
it	-PRON-	PRP	O
was	be	VBD	O
neutralised	neutralise	VBN	O
with	with	IN	O
saturated	saturated	JJ	O
NaHCO3	nahco3	CD	O
solution	solution	NN	O
30	30	CD	O
 	 	_SP	O
ml	ml	NN	O
to	to	TO	O
separate	separate	VB	O
into	into	IN	O
two	two	CD	O
phases	phase	NNS	O
:	:	:	O
the	the	DT	O
organic	organic	JJ	O
phase	phase	NN	O
and	and	CC	O
the	the	DT	O
aqueous	aqueous	JJ	O
phase	phase	NN	O
.	.	.	O

The	the	DT	O
aqueous	aqueous	JJ	O
phase	phase	NN	O
was	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
ethyl	ethyl	NNP	O
acetate	acetate	NNP	O
2	2	CD	O
 	 	_SP	O
×	×	CD	O
 	 	_SP	O
10	10	CD	O
 	 	_SP	O
ml	ml	NN	O
and	and	CC	O
the	the	DT	O
organic	organic	JJ	O
phases	phase	NNS	O
were	be	VBD	O
combined	combine	VBN	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
phase	phase	NN	O
was	be	VBD	O
dried	dry	VBN	O
using	use	VBG	O
anhydrous	anhydrous	JJ	O
magnesium	magnesium	NN	O
sulphate	sulphate	NN	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
the	the	DT	O
solvent	solvent	NN	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
to	to	TO	O
afford	afford	VB	O
the	the	DT	O
products	product	NNS	O
.	.	.	O

Some	some	DT	O
thiazolidin-4-ones	thiazolidin-4-one	NNS	O
5n	5n	CD	O
,	,	,	O
5	5	CD	O
t	t	NN	O
,	,	,	O
5	5	CD	O
 	 	_SP	O
u	u	NN	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6c	6c	NNP	O
,	,	,	O
6e	6e	NNP	O
,	,	,	O
6	6	CD	O
g	g	NN	O
,	,	,	O
6h	6h	CD	O
,	,	,	O
6j	6j	NNP	O
,	,	,	O
6k	6k	CD	O
,	,	,	O
6	6	CD	O
 	 	_SP	O
l	l	NN	O
,	,	,	O
6n	6n	CD	O
,	,	,	O
6p	6p	NNP	O
,	,	,	O
6q	6q	NNP	O
,	,	,	O
6r	6r	NNP	O
,	,	,	O
6x	6x	CD	O
,	,	,	O
6w	6w	NN	O
required	require	VBN	O
purification	purification	NN	O
by	by	IN	O
washing	wash	VBG	O
hot	hot	JJ	O
hexane	hexane	NN	O
or	or	CC	O
hot	hot	JJ	O
hexane	hexane	NN	O
/	/	SYM	O
ethyl	ethyl	NN	O
acetate	acetate	NNP	O
8:2	8:2	CD	O
.	.	.	O

In	in	IN	O
vitro	vitro	FW	O
was	be	VBD	O
evaluated	evaluate	VBN	O
the	the	DT	O
potential	potential	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNPS	O
against	against	IN	O
AChE	AChE	``	O
activity	activity	NN	O
enzyme	enzyme	NNS	O
in	in	IN	O
hippocampus	hippocampus	NNP	O
and	and	CC	O
cerebral	cerebral	JJ	O
cortex	cortex	NN	O
of	of	IN	O
Wistar	Wistar	NNP	O
rats	rat	NNS	O
60	60	CD	O
 	 	_SP	O
days	day	NNS	O
,	,	,	O
250–300	250–300	CD	O
 	 	_SP	O
g	g	NN	O
,	,	,	O
since	since	IN	O
it	-PRON-	PRP	O
is	be	VBZ	O
well	well	RB	O
described	describe	VBN	O
that	that	IN	O
these	these	DT	O
two	two	CD	O
structures	structure	NNS	O
in	in	IN	O
the	the	DT	O
brain	brain	NN	O
play	play	VBP	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
memory	memory	NN	O
.	.	.	O

All	all	DT	O
procedures	procedure	NNS	O
involving	involve	VBG	O
the	the	DT	O
animals	animal	NNS	O
were	be	VBD	O
approved	approve	VBN	O
by	by	IN	O
the	the	DT	O
Committee	Committee	NNP	O
of	of	IN	O
Ethics	Ethics	NNP	O
in	in	IN	O
Animal	Animal	NNP	O
Experimentation	Experimentation	NNP	O
of	of	IN	O
UFPel	UFPel	NNP	O
CEEA	CEEA	NNP	O
9219	9219	CD	O
.	.	.	O

The	the	DT	O
animals	animal	NNS	O
were	be	VBD	O
submitted	submit	VBN	O
to	to	IN	O
euthanasia	euthanasia	NN	O
and	and	CC	O
the	the	DT	O
brain	brain	NN	O
was	be	VBD	O
removed	remove	VBN	O
.	.	.	O

Subsequently	subsequently	RB	O
,	,	,	O
the	the	DT	O
hippocampus	hippocampus	NNP	O
and	and	CC	O
cerebral	cerebral	JJ	O
cortex	cortex	NNP	O
were	be	VBD	O
separated	separate	VBN	O
and	and	CC	O
homogenised	homogenise	VBN	O
in	in	IN	O
buffer	buffer	NN	O
Tris	Tris	NNP	O
HCl	HCl	NNP	O
10	10	CD	O
 	 	_SP	O
mM	mM	NNP	O
pH	pH	NNP	O
7.4	7.4	CD	O
.	.	.	O

The	the	DT	O
homogenates	homogenate	NNS	O
were	be	VBD	O
centrifuged	centrifuge	VBN	O
at	at	IN	O
1800	1800	CD	O
 	 	_SP	O
rpm	rpm	NN	O
for	for	IN	O
10	10	CD	O
 	 	_SP	O
min	min	NN	O
and	and	CC	O
the	the	DT	O
supernatant	supernatant	JJ	O
was	be	VBD	O
used	use	VBN	O
for	for	IN	O
in	in	IN	O
vitro	vitro	FW	O
analyses	analysis	NNS	O
of	of	IN	O
the	the	DT	O
potential	potential	JJ	O
inhibitory	inhibitory	JJ	O
effect	effect	NN	O
of	of	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNPS	O
on	on	IN	O
AChE	AChE	JJS	O
activity	activity	NN	O
.	.	.	O

The	the	DT	O
compounds	compound	NNS	O
were	be	VBD	O
solubilised	solubilise	VBN	O
in	in	IN	O
methanol	methanol	NN	O
and	and	CC	O
prepared	prepare	VBN	O
in	in	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
0.1	0.1	CD	O
,	,	,	O
0.5	0.5	CD	O
,	,	,	O
1	1	CD	O
,	,	,	O
5	5	CD	O
,	,	,	O
10	10	CD	O
,	,	,	O
25	25	CD	O
,	,	,	O
50	50	CD	O
,	,	,	O
100	100	CD	O
and	and	CC	O
250	250	CD	O
 	 	_SP	O
μM	μm	NN	O
.	.	.	O

The	the	DT	O
AChE	AChE	NNP	O
activity	activity	NN	O
was	be	VBD	O
determined	determine	VBN	O
on	on	IN	O
a	a	DT	O
microplate	microplate	NN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
method	method	NN	O
of	of	IN	O
Elmann	Elmann	NNP	O
et	et	NNP	O
 	  	_SP	O
al	al	NNP	O
.	.	NNP	B
which	which	WDT	O
demonstrates	demonstrate	VBZ	O
as	as	IN	O
a	a	DT	O
principle	principle	NN	O
the	the	DT	O
hydrolysis	hydrolysis	NN	O
of	of	IN	O
the	the	DT	O
substrate	substrate	NN	O
acetylcholine	acetylcholine	NN	O
which	which	WDT	O
is	be	VBZ	O
converted	convert	VBN	O
into	into	IN	O
two	two	CD	O
products	product	NNS	O
,	,	,	O
acetate	acetate	JJ	O
and	and	CC	O
thiocoline	thiocoline	NN	O
.	.	.	O

The	the	DT	O
thiocholine	thiocholine	NN	O
,	,	,	O
in	in	IN	O
turn	turn	NN	O
,	,	,	O
reacts	react	NNS	O
with	with	IN	O
DTNB	DTNB	NNP	O
to	to	TO	O
form	form	VB	O
a	a	DT	O
chromophore	chromophore	NN	O
,	,	,	O
5-thio-2-nitrobenzoic	5-thio-2-nitrobenzoic	CD	O
,	,	,	O
which	which	WDT	O
is	be	VBZ	O
quantified	quantify	VBN	O
spectrophotometrically	spectrophotometrically	RB	O
at	at	IN	O
412	412	CD	O
 	 	_SP	O
nm	nm	NN	O
.	.	.	O

The	the	DT	O
enzymatic	enzymatic	JJ	O
activity	activity	NN	O
was	be	VBD	O
expressed	express	VBN	O
in	in	IN	O
μmols	μmol	NNS	O
of	of	IN	O
AcSCh	AcSCh	NNP	O
/	/	SYM	O
h	h	NNP	O
/	/	SYM	O
mg	mg	NNP	O
protein	protein	NN	O
.	.	.	O

Proteins	protein	NNS	O
were	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
the	the	DT	O
method	method	NN	O
of	of	IN	O
BradfordCYTOWANIE	BradfordCYTOWANIE	NNP	O
using	use	VBG	O
the	the	DT	O
Coomassie	Coomassie	NNP	O
Blue	Blue	NNP	O
reagent	reagent	NN	O
.	.	.	O

Bovine	bovine	JJ	O
albumin	albumin	NN	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
standard	standard	JJ	O
.	.	.	O

It	-PRON-	PRP	O
was	be	VBD	O
emphasised	emphasise	VBN	O
that	that	IN	O
besides	besides	IN	O
the	the	DT	O
water	water	NN	O
control	control	NN	O
,	,	,	O
the	the	DT	O
action	action	NN	O
of	of	IN	O
methanol	methanol	NN	O
on	on	IN	O
AChE	AChE	``	O
activity	activity	NN	O
was	be	VBD	O
also	also	RB	O
determined	determine	VBN	O
,	,	,	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
confirm	confirm	VB	O
that	that	IN	O
the	the	DT	O
solvent	solvent	NN	O
does	do	VBZ	O
not	not	RB	O
interfere	interfere	VB	O
with	with	IN	O
the	the	DT	O
enzymatic	enzymatic	JJ	O
activity	activity	NN	O
.	.	.	O

Based	base	VBN	O
on	on	IN	O
the	the	DT	O
results	result	NNS	O
,	,	,	O
it	-PRON-	PRP	O
can	can	MD	O
be	be	VB	O
shown	show	VBN	O
that	that	IN	O
methanol	methanol	NN	O
did	do	VBD	O
not	not	RB	O
alter	alter	VB	O
AChE	AChE	''	O
activity	activity	NN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
water	water	NN	O
control	control	NN	O
group	group	NN	O
p	p	NN	O
 	 	_SP	O
>	>	NN	O
 	 	_SP	O
.05	.05	NFP	O
.	.	.	O

In	in	IN	O
the	the	DT	O
evaluation	evaluation	NN	O
of	of	IN	O
the	the	DT	O
cytotoxicity	cytotoxicity	NN	O
of	of	IN	O
the	the	DT	O
thiazolidin-4-ones	thiazolidin-4-ones	NNPS	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNPS	O
in	in	IN	O
astrocytes	astrocyte	NNS	O
,	,	,	O
Wistar	Wistar	NNP	O
rats	rat	NNS	O
1–2	1–2	CD	O
 	 	_SP	O
days	day	NNS	O
were	be	VBD	O
used	use	VBN	O
to	to	TO	O
obtain	obtain	VB	O
cortical	cortical	JJ	O
astrocytes	astrocyte	NNS	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
cultured	culture	VBN	O
in	in	IN	O
96-well	96-well	CD	O
plates	plate	NNS	O
3x104	3x104	CD	O
per	per	IN	O
well	well	RB	O
and	and	CC	O
maintained	maintain	VBN	O
with	with	IN	O
Dulbecco	Dulbecco	NNP	O
’s	’s	POS	O
modified	modify	VBN	O
Eagle	Eagle	NNP	O
’s	’s	POS	O
medium	medium	NN	O
DMEM	DMEM	NNP	O
supplemented	supplement	VBD	O
with	with	IN	O
10	10	CD	O
%	%	NN	O
Bovine	Bovine	NNP	O
Foetal	Foetal	NNP	O
Serum	Serum	NNP	O
FBS)CYTOWANIE	fbs)cytowanie	NN	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
maintained	maintain	VBN	O
under	under	IN	O
standard	standard	JJ	O
conditions	condition	NNS	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
,	,	,	O
37	37	CD	O
 	 	_SP	O
°	°	NNS	O
C	C	NNP	O
and	and	CC	O
humidified	humidify	VBN	O
atmosphere	atmosphere	NN	O
for	for	IN	O
15	15	CD	O
 	 	_SP	O
days	day	NNS	O
,	,	,	O
receiving	receive	VBG	O
periodic	periodic	JJ	O
exchange	exchange	NN	O
of	of	IN	O
culture	culture	NN	O
medium	medium	NN	O
until	until	IN	O
treatments	treatment	NNS	O
were	be	VBD	O
received	receive	VBN	O
.	.	.	O

After	after	IN	O
time	time	NN	O
and	and	CC	O
maturation	maturation	NN	O
,	,	,	O
the	the	DT	O
astrocytes	astrocytes	NNPS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
the	the	DT	O
compounds	compound	NNS	O
at	at	IN	O
the	the	DT	O
concentration	concentration	NN	O
of	of	IN	O
100	100	CD	O
 	 	_SP	O
μM.	μM.	NNP	O
Cells	cell	NNS	O
were	be	VBD	O
exposed	expose	VBN	O
to	to	IN	O
this	this	DT	O
concentration	concentration	NN	O
for	for	IN	O
48	48	CD	O
 	 	_SP	O
h	h	NN	O
and	and	CC	O
72	72	CD	O
 	 	_SP	O
h.	h.	NN	O
After	after	IN	O
treatment	treatment	NN	O
,	,	,	O
cell	cell	NN	O
viability	viability	NN	O
was	be	VBD	O
analysed	analyse	VBN	O
by	by	IN	O
the	the	DT	O
test	test	NN	O
of	of	IN	O
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium	3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium	CD	O
bromide	bromide	NN	O
MTT	MTT	NNP	O
.	.	.	O

This	this	DT	O
method	method	NN	O
consists	consist	VBZ	O
of	of	IN	O
measuring	measure	VBG	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
cells	cell	NNS	O
with	with	IN	O
the	the	DT	O
metabolically	metabolically	RB	O
active	active	JJ	O
mitochondria	mitochondria	NNP	O
,	,	,	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
reduction	reduction	NN	O
of	of	IN	O
the	the	DT	O
tetrazolium	tetrazolium	NN	O
salt	salt	NN	O
to	to	IN	O
the	the	DT	O
formazan	formazan	JJ	O
crystals	crystal	NNS	O
.	.	.	O

The	the	DT	O
absorbance	absorbance	NN	O
was	be	VBD	O
determined	determine	VBN	O
on	on	IN	O
a	a	DT	O
microplate	microplate	NN	O
reader	reader	NN	O
at	at	IN	O
492	492	CD	O
 	 	_SP	O
nm	nm	NN	O
.	.	.	O

The	the	DT	O
absorbance	absorbance	NN	O
is	be	VBZ	O
linearly	linearly	RB	O
proportional	proportional	JJ	O
to	to	IN	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
cells	cell	NNS	O
with	with	IN	O
active	active	JJ	O
mitochondria	mitochondrion	NNS	O
,	,	,	O
indicating	indicate	VBG	O
how	how	WRB	O
many	many	JJ	O
viable	viable	JJ	O
cells	cell	NNS	O
remained	remain	VBD	O
at	at	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
the	the	DT	O
treatment	treatment	NN	O
.	.	.	O

Results	result	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
by	by	IN	O
using	use	VBG	O
one	one	CD	O
-	-	HYPH	O
way	way	NN	O
analysis	analysis	NN	O
of	of	IN	O
variance	variance	NN	O
ANOVA	ANOVA	NNP	O
followed	follow	VBN	O
by	by	IN	O
Tukey	Tukey	NNP	O
test	test	NN	O
for	for	IN	O
multiple	multiple	JJ	O
comparisons	comparison	NNS	O
in	in	IN	O
the	the	DT	O
software	software	NN	O
Graphpad	Graphpad	NNP	O
Prism	Prism	NNP	O
5	5	CD	O
.	.	.	O

The	the	DT	O
statistical	statistical	JJ	O
difference	difference	NN	O
was	be	VBD	O
considered	consider	VBN	O
significant	significant	JJ	O
when	when	WRB	O
p	p	NN	O
 	 	_SP	O
<	<	XX	O
 	 	_SP	O
.05	.05	NFP	O
and	and	CC	O
all	all	DT	O
results	result	NNS	O
were	be	VBD	O
expressed	express	VBN	O
as	as	IN	O
mean	mean	JJ	O
 	 	_SP	O
±	±	CD	O
 	 	_SP	O
standard	standard	JJ	O
error	error	NN	O
.	.	.	O

In	in	IN	O
continuation	continuation	NN	O
of	of	IN	O
our	-PRON-	PRP$	O
research	research	NN	O
programme	programme	NN	O
,	,	,	O
the	the	DT	O
synthetic	synthetic	JJ	O
route	route	NN	O
used	use	VBN	O
to	to	TO	O
synthesise	synthesise	VB	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
5	5	CD	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-one	NNS	O
6	6	CD	O
is	be	VBZ	O
illustrated	illustrate	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
1	1	CD	O
.	.	.	O

Mercaptoacetic	mercaptoacetic	JJ	O
acid	acid	NN	O
4a	4a	NNP	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
obtain	obtain	VB	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
5	5	CD	O
and	and	CC	O
mercaptopropionic	mercaptopropionic	JJ	O
acid	acid	NN	O
4b	4b	NNP	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
obtain	obtain	VB	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6	6	CD	O
.	.	.	O

It	-PRON-	PRP	O
was	be	VBD	O
used	use	VBN	O
arenealdehydes	arenealdehyde	NNS	O
2	2	CD	O
with	with	IN	O
substituents	substituent	NNS	O
in	in	IN	O
ortho	ortho	NNP	O
,	,	,	O
meta	meta	JJ	O
and	and	CC	O
para	para	NNP	O
positions	position	NNS	O
,	,	,	O
with	with	IN	O
electron	electron	NN	O
-	-	HYPH	O
donating	donate	VBG	O
groups	group	NNS	O
CH3	CH3	NNP	O
,	,	,	O
OH	oh	UH	O
,	,	,	O
OCH3	OCH3	NNP	O
and	and	CC	O
electron	electron	NN	O
-	-	HYPH	O
withdrawing	withdraw	VBG	O
groups	group	NNS	O
F	F	NNP	O
,	,	,	O
Cl	Cl	NNP	O
,	,	,	O
NO2	NO2	NNP	O
.	.	.	O

Accordingly	accordingly	RB	O
,	,	,	O
the	the	DT	O
1-(2-aminoethyl)pyrrolidine	1-(2-aminoethyl)pyrrolidine	CD	O
1	1	CD	O
reacts	react	NNS	O
with	with	IN	O
different	different	JJ	O
benzaldehydes	benzaldehyde	NNS	O
2a	2a	CD	O
-	-	HYPH	O
x	x	NNP	O
and	and	CC	O
an	an	DT	O
appropriate	appropriate	JJ	O
carboxylic	carboxylic	JJ	O
acid	acid	NN	O
4a	4a	NNP	O
-	-	HYPH	O
b	b	NN	O
in	in	IN	O
toluene	toluene	JJ	O
reflux	reflux	NN	O
for	for	IN	O
5	5	CD	O
 	 	_SP	O
h	h	NN	O
to	to	TO	O
give	give	VB	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
5a	5a	NNP	O
-	-	HYPH	O
u	u	NN	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6a	6a	NNP	O
-	-	HYPH	O
s	s	NNPS	O
,	,	,	O
v	v	NNP	O
-	-	HYPH	O
x	x	NNP	O
.	.	.	O

Synthetic	synthetic	JJ	O
pathway	pathway	NN	O
to	to	IN	O
the	the	DT	O
obtention	obtention	NN	O
of	of	IN	O
thiazolidinones	thiazolidinone	NNS	O
and	and	CC	O
thiazinanones	thiazinanone	NNS	O
.	.	.	O

During	during	IN	O
the	the	DT	O
process	process	NN	O
,	,	,	O
the	the	DT	O
reactions	reaction	NNS	O
were	be	VBD	O
monitored	monitor	VBN	O
by	by	IN	O
thin	thin	JJ	O
-	-	HYPH	O
layer	layer	NN	O
chromatography	chromatography	NN	O
TLC	TLC	NNP	O
and	and	CC	O
some	some	DT	O
products	product	NNS	O
required	require	VBD	O
a	a	DT	O
purification	purification	NN	O
step	step	NN	O
by	by	IN	O
washing	wash	VBG	O
with	with	IN	O
hot	hot	JJ	O
hexane	hexane	NN	O
or	or	CC	O
hot	hot	JJ	O
hexane	hexane	NN	O
/	/	SYM	O
ethyl	ethyl	NN	O
acetate	acetate	NNP	O
8:2	8:2	CD	O
.	.	.	O

The	the	DT	O
products	product	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
with	with	IN	O
good	good	JJ	O
to	to	TO	O
moderate	moderate	VB	O
yields	yield	NNS	O
and	and	CC	O
the	the	DT	O
melting	melting	NN	O
point	point	NN	O
analysis	analysis	NN	O
was	be	VBD	O
performed	perform	VBN	O
for	for	IN	O
the	the	DT	O
solid	solid	JJ	O
compounds	compound	NNS	O
.	.	.	O

All	all	DT	O
compounds	compound	NNS	O
were	be	VBD	O
characterised	characterise	VBN	O
and	and	CC	O
confirmed	confirm	VBN	O
by	by	IN	O
GC	GC	NNP	O
/	/	SYM	O
MS	MS	NNP	O
and	and	CC	O
1H	1H	NNP	O
,	,	,	O
13	13	CD	O
 	 	_SP	O
C	C	NNP	O
NMR	NMR	NNP	O
analyses	analyse	VBZ	O
.	.	.	O

Compound	Compound	NNP	O
5i	5i	NNP	O
has	have	VBZ	O
also	also	RB	O
been	be	VBN	O
analysed	analyse	VBN	O
in	in	IN	O
2	2	CD	O
 	 	_SP	O
D	d	NN	O
NMR	NMR	NNP	O
COSY	COSY	NNP	O
,	,	,	O
HSQC	HSQC	NNP	O
,	,	,	O
HMBC	HMBC	NNP	O
.	.	.	O

Compounds	Compounds	NNP	O
5d	5d	NNP	O
,	,	,	O
5	5	CD	O
 	 	_SP	O
g	g	NN	O
,	,	,	O
5j	5j	NNP	O
,	,	,	O
5k	5k	CD	O
and	and	CC	O
5o	5o	NNS	O
were	be	VBD	O
also	also	RB	O
identified	identify	VBN	O
by	by	IN	O
HRMS	HRMS	NNP	O
.	.	.	O

In	in	IN	O
the	the	DT	O
1H	1h	JJ	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
,	,	,	O
the	the	DT	O
signals	signal	NNS	O
that	that	WDT	O
confirm	confirm	VBP	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
are	be	VBP	O
the	the	DT	O
H2	H2	NNP	O
and	and	CC	O
the	the	DT	O
diastereopic	diastereopic	JJ	O
H5	H5	NNP	O
hydrogens	hydrogen	VBZ	O
.	.	.	O

For	for	IN	O
thiazinan-4-one	thiazinan-4-one	NNP	O
the	the	DT	O
signals	signal	NNS	O
are	be	VBP	O
the	the	DT	O
H2	H2	NNP	O
and	and	CC	O
diastereopic	diastereopic	NNP	O
H5	H5	NNP	O
and	and	CC	O
H6	H6	NNP	O
hydrogens	hydrogen	VBZ	O
.	.	.	O

For	for	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
5	5	CD	O
,	,	,	O
hydrogen	hydrogen	NNP	O
H5a	H5a	NNP	O
appears	appear	VBZ	O
as	as	IN	O
a	a	DT	O
double	double	JJ	O
doublet	doublet	NN	O
and	and	CC	O
H5b	h5b	NN	O
as	as	IN	O
a	a	DT	O
doublet	doublet	NN	O
signal	signal	NN	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
3	3	CD	O
to	to	TO	O
4	4	CD	O
 	 	_SP	O
ppm	ppm	NN	O
.	.	.	O

For	for	IN	O
thiazinan-4-one	thiazinan-4-one	NNP	O
6	6	CD	O
,	,	,	O
H5a	H5a	NNP	O
,	,	,	O
H5b	H5b	NNP	O
,	,	,	O
H6a	h6a	UH	O
and	and	CC	O
H6b	h6b	NN	O
appear	appear	VBP	O
as	as	IN	O
multiplets	multiplet	NNS	O
due	due	IN	O
to	to	IN	O
overlapping	overlapping	NN	O
of	of	IN	O
signals	signal	NNS	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
2	2	CD	O
to	to	TO	O
3	3	CD	O
 	 	_SP	O
ppm	ppm	NN	O
with	with	IN	O
spectral	spectral	JJ	O
signal	signal	NN	O
of	of	IN	O
H6	H6	NNP	O
more	more	RBR	O
deshielded	deshielded	JJ	O
than	than	IN	O
H5	H5	NNP	O
.	.	.	O

Another	another	DT	O
characteristic	characteristic	JJ	O
signal	signal	NN	O
present	present	NN	O
in	in	IN	O
both	both	DT	O
heterocycles	heterocycle	NNS	O
is	be	VBZ	O
the	the	DT	O
H2	H2	NNP	O
belonging	belong	VBG	O
to	to	IN	O
the	the	DT	O
asymmetric	asymmetric	JJ	O
carbon	carbon	NN	O
C2	c2	NN	O
that	that	WDT	O
appears	appear	VBZ	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
5	5	CD	O
to	to	TO	O
6	6	CD	O
 	 	_SP	O
ppm	ppm	NN	O
as	as	IN	O
singlet	singlet	JJ	O
or	or	CC	O
doublet	doublet	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
13	13	CD	O
 	 	_SP	O
C	C	NNP	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
,	,	,	O
the	the	DT	O
characteristic	characteristic	JJ	O
signals	signal	NNS	O
of	of	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
and	and	CC	O
thiazinan-4-one	thiazinan-4-one	NNP	O
are	be	VBP	O
C4	c4	JJ	O
,	,	,	O
C2	c2	NN	O
and	and	CC	O
C5	C5	NNP	O
plus	plus	CC	O
C6	C6	NNP	O
for	for	IN	O
thiazinan-4-one	thiazinan-4-one	NNP	O
.	.	.	O

The	the	DT	O
carbonyl	carbonyl	NN	O
C4	c4	NN	O
is	be	VBZ	O
the	the	DT	O
most	most	RBS	O
deshielded	deshielded	JJ	O
signal	signal	NN	O
in	in	IN	O
the	the	DT	O
spectrum	spectrum	NN	O
at	at	IN	O
170	170	CD	O
 	 	_SP	O
ppm	ppm	NN	O
.	.	.	O

The	the	DT	O
methyne	methyne	NN	O
C2	c2	NN	O
appears	appear	VBZ	O
at	at	IN	O
55.9	55.9	CD	O
-	-	HYPH	O
64.1	64.1	CD	O
 	 	_SP	O
ppm	ppm	NN	O
for	for	IN	O
both	both	DT	O
heterocycles	heterocycle	NNS	O
.	.	.	O

The	the	DT	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
5	5	CD	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-one	NNS	O
6	6	CD	O
have	have	VBP	O
the	the	DT	O
sign	sign	NN	O
of	of	IN	O
C5	c5	NN	O
in	in	IN	O
the	the	DT	O
region	region	NN	O
of	of	IN	O
31.6–34.8	31.6–34.8	CD	O
 	 	_SP	O
ppm	ppm	NN	O
.	.	.	O

The	the	DT	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6	6	CD	O
also	also	RB	O
have	have	VBP	O
the	the	DT	O
sign	sign	NN	O
of	of	IN	O
C6	c6	NN	O
in	in	IN	O
the	the	DT	O
region	region	NN	O
of	of	IN	O
23.3	23.3	CD	O
-	-	HYPH	O
21.2	21.2	CD	O
 	 	_SP	O
ppm	ppm	NN	O
.	.	.	O

Other	other	JJ	O
signals	signal	NNS	O
belong	belong	VBP	O
to	to	IN	O
the	the	DT	O
amine	amine	NN	O
and	and	CC	O
corresponding	correspond	VBG	O
arenealdehyde	arenealdehyde	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
COSY	COSY	NNP	O
spectrum	spectrum	NN	O
of	of	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
5i	5i	CD	O
it	-PRON-	PRP	O
was	be	VBD	O
possible	possible	JJ	O
to	to	TO	O
confirm	confirm	VB	O
the	the	DT	O
H2	H2	NNP	O
at	at	IN	O
6.00	6.00	CD	O
 	 	_SP	O
ppm	ppm	NN	O
because	because	IN	O
coupling	couple	VBG	O
with	with	IN	O
the	the	DT	O
diastereopic	diastereopic	JJ	O
hydrogen	hydrogen	NN	O
H5a	h5a	NN	O
at	at	IN	O
3.80	3.80	CD	O
 	 	_SP	O
ppm	ppm	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
HMQC	HMQC	NNP	O
spectrum	spectrum	NN	O
the	the	DT	O
carbon	carbon	NN	O
of	of	IN	O
diastereopic	diastereopic	NNP	O
hydrogens	hydrogens	NNP	O
H5a	H5a	NNP	O
and	and	CC	O
H5b	H5b	NNP	O
was	be	VBD	O
verified	verify	VBN	O
at	at	IN	O
32	32	CD	O
 	 	_SP	O
ppm	ppm	NN	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
it	-PRON-	PRP	O
is	be	VBZ	O
also	also	RB	O
important	important	JJ	O
to	to	TO	O
show	show	VB	O
the	the	DT	O
elucidation	elucidation	NN	O
the	the	DT	O
C6	C6	NNP	O
and	and	CC	O
C7	C7	NNP	O
for	for	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
5i	5i	CD	O
about	about	RB	O
41	41	CD	O
and	and	CC	O
54	54	CD	O
 	 	_SP	O
ppm	ppm	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

There	there	EX	O
is	be	VBZ	O
a	a	DT	O
chemical	chemical	JJ	O
displacement	displacement	NN	O
inversion	inversion	NN	O
between	between	IN	O
C6	C6	NNP	O
and	and	CC	O
C7	C7	NNP	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
respective	respective	JJ	O
hydrogens	hydrogen	VBZ	O
H6	H6	NNP	O
and	and	CC	O
H7	H7	NNP	O
.	.	.	O

The	the	DT	O
H6	H6	NNP	O
has	have	VBZ	O
a	a	DT	O
deshielded	deshielde	VBN	O
signal	signal	NN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
H7	h7	NN	O
,	,	,	O
however	however	RB	O
C6	C6	NNP	O
has	have	VBZ	O
a	a	DT	O
shielded	shielded	JJ	O
signal	signal	NN	O
compared	compare	VBN	O
to	to	IN	O
C7	C7	NNP	O
.	.	.	O

A	a	DT	O
possible	possible	JJ	O
explanation	explanation	NN	O
is	be	VBZ	O
due	due	JJ	O
the	the	DT	O
conformational	conformational	JJ	O
freedom	freedom	NN	O
of	of	IN	O
ethylene	ethylene	NN	O
link	link	NN	O
.	.	.	O

The	the	DT	O
HMBC	HMBC	NNP	O
spectrum	spectrum	NN	O
confirms	confirm	VBZ	O
these	these	DT	O
assignments	assignment	NNS	O
.	.	.	O

In	in	IN	O
cerebral	cerebral	JJ	O
cortex	cortex	NN	O
,	,	,	O
compounds	compound	VBZ	O
5j	5j	NNP	O
and	and	CC	O
6h	6h	CD	O
inhibited	inhibit	VBN	O
AChE	AChE	''	O
activity	activity	NN	O
from	from	IN	O
the	the	DT	O
concentration	concentration	NN	O
of	of	IN	O
1	1	CD	O
 	 	_SP	O
μM	μM	NNP	O
,	,	,	O
while	while	IN	O
compounds	compound	VBZ	O
6a	6a	NNP	O
,	,	,	O
6n	6n	CD	O
and	and	CC	O
6k	6k	CD	O
from	from	IN	O
5	5	CD	O
 	 	_SP	O
μM	μm	NN	O
and	and	CC	O
compound	compound	VB	O
6j	6j	NNS	O
from	from	IN	O
10	10	CD	O
 	 	_SP	O
μM	μM	NNP	O
Figure	Figure	NNP	O
2	2	CD	O
.	.	.	O

In	in	IN	O
the	the	DT	O
hippocampus	hippocampus	NN	O
,	,	,	O
compounds	compound	VBZ	O
5j	5j	NNP	O
,	,	,	O
6a	6a	CD	O
,	,	,	O
6j	6j	NNP	O
,	,	,	O
6k	6k	CD	O
and	and	CC	O
6n	6n	CD	O
inhibited	inhibit	VBN	O
AChE	AChE	''	O
activity	activity	NN	O
from	from	IN	O
1	1	CD	O
 	 	_SP	O
μM	μM	NNP	O
,	,	,	O
when	when	WRB	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
water	water	NN	O
and	and	CC	O
methanol	methanol	NN	O
p	p	NN	O
 	 	_SP	O
<	<	XX	O
 	 	_SP	O
.05	.05	NFP	O
Figure	figure	NN	O
3	3	CD	O
.	.	.	O

The	the	DT	O
compound	compound	NN	O
6	6	CD	O
 	 	_SP	O
h	h	NN	O
inhibited	inhibit	VBD	O
the	the	DT	O
AChE	AChE	NNP	O
activity	activity	NN	O
of	of	IN	O
hippocampus	hippocampus	NNP	O
at	at	IN	O
concentration	concentration	NN	O
of	of	IN	O
5	5	CD	O
 	 	_SP	O
μM	μM	NNP	O
Figure	Figure	NNP	O
3	3	CD	O
.	.	.	O

In	in	IN	O
vitro	vitro	FW	O
effect	effect	NN	O
of	of	IN	O
compounds	compound	NNS	O
5j	5j	NNP	O
,	,	,	O
6a	6a	CD	O
,	,	,	O
6	6	CD	O
 	 	_SP	O
h	h	NN	O
,	,	,	O
6j	6j	NNP	O
,	,	,	O
6k	6k	CD	O
and	and	CC	O
6n	6n	CD	O
on	on	IN	O
the	the	DT	O
activity	activity	NN	O
of	of	IN	O
AChE	AChE	``	O
in	in	IN	O
cerebral	cerebral	JJ	O
cortex	cortex	NN	O
of	of	IN	O
rats	rat	NNS	O
.	.	.	O

*	*	NFP	O
p	p	NN	O
 	 	_SP	O
<	<	XX	O
 	 	_SP	O
.05	.05	NNS	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
p	p	NN	O
 	 	_SP	O
<	<	XX	O
 	 	_SP	O
.01	.01	NNS	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
*	*	NFP	O
p	p	NN	O
 	 	_SP	O
<	<	XX	O
 	 	_SP	O
.001	.001	CD	O
when	when	WRB	O
compared	compare	VBN	O
to	to	TO	O
control	control	VB	O
group	group	NN	O
water	water	NN	O
or	or	CC	O
MeOH	MeOH	NNP	O
.	.	.	O

In	in	IN	O
vitro	vitro	FW	O
effect	effect	NN	O
of	of	IN	O
compounds	compound	NNS	O
5j	5j	NNP	O
,	,	,	O
6a	6a	CD	O
,	,	,	O
6	6	CD	O
 	 	_SP	O
h	h	NN	O
,	,	,	O
6j	6j	NNP	O
,	,	,	O
6k	6k	CD	O
and	and	CC	O
6n	6n	CD	O
on	on	IN	O
the	the	DT	O
activity	activity	NN	O
of	of	IN	O
AChE	AChE	``	O
in	in	IN	O
cerebral	cerebral	JJ	O
hippocampus	hippocampus	NN	O
of	of	IN	O
rats	rat	NNS	O
.	.	.	O

*	*	NFP	O
p	p	NN	O
 	 	_SP	O
<	<	XX	O
 	 	_SP	O
.05	.05	NNS	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
p	p	NN	O
 	 	_SP	O
<	<	XX	O
 	 	_SP	O
.01	.01	NNS	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
*	*	NFP	O
p	p	NN	O
 	 	_SP	O
<	<	XX	O
 	 	_SP	O
.001	.001	CD	O
when	when	WRB	O
compared	compare	VBN	O
to	to	TO	O
control	control	VB	O
group	group	NN	O
water	water	NN	O
or	or	CC	O
MeOH	MeOH	NNP	O
.	.	.	O

In	in	IN	O
cerebral	cerebral	JJ	O
cortex	cortex	NNP	O
,	,	,	O
the	the	DT	O
compounds	compound	NNS	O
5i	5i	CD	O
inhibited	inhibit	VBN	O
AChE	AChE	''	O
activity	activity	NN	O
from	from	IN	O
10	10	CD	O
 	 	_SP	O
μM	μM	NNP	O
,	,	,	O
6	6	CD	O
m	m	NNP	O
and	and	CC	O
6o	6o	NNP	O
from	from	IN	O
25	25	CD	O
 	 	_SP	O
μM	μm	NN	O
,	,	,	O
6i	6i	CD	O
from	from	IN	O
50	50	CD	O
 	 	_SP	O
μM	μm	NN	O
and	and	CC	O
6l	6l	IN	O
from	from	IN	O
100	100	CD	O
 	 	_SP	O
μM	μM	NNP	O
when	when	WRB	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
water	water	NN	O
and	and	CC	O
methanol	methanol	NN	O
p	p	NN	O
 	 	_SP	O
<	<	XX	O
 	 	_SP	O
.05	.05	NFP	O
.	.	.	O

In	in	IN	O
the	the	DT	O
hippocampus	hippocampus	NN	O
,	,	,	O
compound	compound	NNP	O
5i	5i	NNP	O
inhibited	inhibit	VBD	O
the	the	DT	O
AChE	AChE	NNP	O
activity	activity	NN	O
from	from	IN	O
10	10	CD	O
 	 	_SP	O
μM	μM	NNP	O
,	,	,	O
6n	6n	CD	O
from	from	IN	O
25	25	CD	O
 	 	_SP	O
μM	μm	NN	O
,	,	,	O
6i	6i	CD	O
from	from	IN	O
50	50	CD	O
 	 	_SP	O
μM	μm	NN	O
and	and	CC	O
6	6	CD	O
 	 	_SP	O
l	l	NN	O
from	from	IN	O
100	100	CD	O
 	 	_SP	O
μM	μM	NNP	O
concentrations	concentration	NNS	O
.	.	.	O

A	a	DT	O
decrease	decrease	NN	O
in	in	IN	O
activity	activity	NN	O
was	be	VBD	O
found	find	VBN	O
for	for	IN	O
the	the	DT	O
disubstituted	disubstitute	VBN	O
thiazinanone	thiazinanone	NN	O
6p	6p	CD	O
.	.	.	O

These	these	DT	O
findings	finding	NNS	O
showed	show	VBD	O
that	that	IN	O
groups	group	NNS	O
in	in	IN	O
para	para	NNP	O
position	position	NN	O
still	still	RB	O
had	have	VBD	O
better	well	JJR	O
results	result	NNS	O
.	.	.	O

Based	base	VBN	O
on	on	IN	O
the	the	DT	O
results	result	NNS	O
obtained	obtain	VBN	O
,	,	,	O
it	-PRON-	PRP	O
can	can	MD	O
be	be	VB	O
observed	observe	VBN	O
that	that	IN	O
the	the	DT	O
molecules	molecule	NNS	O
with	with	IN	O
the	the	DT	O
most	most	RBS	O
promising	promising	JJ	O
inhibitory	inhibitory	JJ	O
potential	potential	NN	O
against	against	IN	O
AChE	AChE	``	O
activity	activity	NN	O
were	be	VBD	O
:	:	:	O
5j	5j	NNP	O
,	,	,	O
6a	6a	CD	O
,	,	,	O
6h	6h	CD	O
,	,	,	O
6j	6j	NNP	O
,	,	,	O
6k	6k	CD	O
and	and	CC	O
6n	6n	NNP	O
.	.	.	O

So	so	RB	O
,	,	,	O
the	the	DT	O
cytotoxicity	cytotoxicity	NN	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
was	be	VBD	O
evaluated	evaluate	VBN	O
using	use	VBG	O
cortical	cortical	JJ	O
astrocyte	astrocyte	NNS	O
cells	cell	NNS	O
cultured	culture	VBN	O
in	in	IN	O
96-well	96-well	CD	O
plates	plate	NNS	O
for	for	IN	O
15	15	CD	O
 	 	_SP	O
days	day	NNS	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
exposed	expose	VBN	O
to	to	IN	O
the	the	DT	O
compounds	compound	NNS	O
at	at	IN	O
the	the	DT	O
concentration	concentration	NN	O
of	of	IN	O
100	100	CD	O
 	 	_SP	O
μM	μm	NN	O
for	for	IN	O
48	48	CD	O
 	 	_SP	O
h	h	NN	O
and	and	CC	O
72	72	CD	O
 	 	_SP	O
h.	h.	NN	O
After	after	IN	O
treatment	treatment	NN	O
,	,	,	O
cell	cell	NN	O
viability	viability	NN	O
was	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
the	the	DT	O
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl	3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl	CD	O
-	-	HYPH	O
tetrazoline	tetrazoline	NN	O
MTT	MTT	NNP	O
bromide	bromide	NN	O
test	test	NN	O
.	.	.	O

Our	-PRON-	PRP$	O
results	result	NNS	O
showed	show	VBD	O
that	that	IN	O
none	none	NN	O
of	of	IN	O
the	the	DT	O
tested	test	VBN	O
compounds	compound	NNS	O
were	be	VBD	O
able	able	JJ	O
to	to	TO	O
alter	alter	VB	O
the	the	DT	O
cell	cell	NN	O
viability	viability	NN	O
of	of	IN	O
astrocyte	astrocyte	JJ	O
primary	primary	JJ	O
culture	culture	NN	O
at	at	IN	O
the	the	DT	O
concentration	concentration	NN	O
of	of	IN	O
100	100	CD	O
 	 	_SP	O
μM	μm	NN	O
in	in	IN	O
both	both	DT	O
times	time	NNS	O
p	p	NN	O
 	 	_SP	O
>	>	NN	O
 	 	_SP	O
.05	.05	NFP	O
Figure	figure	NN	O
4	4	CD	O
.	.	.	O

In	in	IN	O
vitro	vitro	FW	O
cytotoxicity	cytotoxicity	NN	O
activity	activity	NN	O
of	of	IN	O
compounds	compound	NNS	O
5j	5j	NNP	O
,	,	,	O
6a	6a	CD	O
,	,	,	O
6	6	CD	O
 	 	_SP	O
h	h	NN	O
,	,	,	O
6j	6j	NNP	O
,	,	,	O
6k	6k	CD	O
and	and	CC	O
6n	6n	CD	O
to	to	TO	O
cell	cell	VB	O
viability	viability	NN	O
of	of	IN	O
the	the	DT	O
primary	primary	JJ	O
astrocyte	astrocyte	NN	O
culture	culture	NN	O
at	at	IN	O
100	100	CD	O
 	 	_SP	O
μM	μM	NNP	O
,	,	,	O
after	after	IN	O
for	for	IN	O
48	48	CD	O
 	 	_SP	O
h	h	NN	O
A	a	NN	O
and	and	CC	O
72	72	CD	O
 	 	_SP	O
h	h	NN	O
B	b	NN	O
the	the	DT	O
treatment	treatment	NN	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
for	for	IN	O
the	the	DT	O
most	most	RBS	O
promising	promising	JJ	O
compounds	compound	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
using	use	VBG	O
GraphPad	GraphPad	NNP	O
Prism	Prism	NNP	O
5	5	CD	O
programme	programme	NN	O
Table	table	NN	O
1	1	CD	O
.	.	.	O

Compound	Compound	NNP	O
6k	6k	CD	O
was	be	VBD	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
with	with	IN	O
IC50	IC50	NNP	O
=	=	SYM	O
6.83	6.83	CD	O
 	 	_SP	O
µM	µM	NNP	O
for	for	IN	O
cerebral	cerebral	NNP	O
cortex	cortex	NNP	O
and	and	CC	O
IC50	IC50	NNP	O
=	=	SYM	O
4.46	4.46	CD	O
 	 	_SP	O
µM	µM	NNP	O
for	for	IN	O
hippocampus	hippocampus	NNP	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
compound	compound	NNP	O
6a	6a	NNP	O
also	also	RB	O
demonstrated	demonstrate	VBD	O
good	good	JJ	O
inhibition	inhibition	NN	O
activity	activity	NN	O
of	of	IN	O
AChE	AChE	``	O
with	with	IN	O
IC50	IC50	NNP	O
=	=	SYM	O
7.40	7.40	CD	O
 	 	_SP	O
µM	µM	NNP	O
for	for	IN	O
cerebral	cerebral	NNP	O
cortex	cortex	NNP	O
and	and	CC	O
IC50	IC50	NNP	O
=	=	SYM	O
5.20	5.20	CD	O
 	 	_SP	O
µM	µM	NNP	O
for	for	IN	O
hippocampus	hippocampus	NNP	O
.	.	.	O

Other	other	JJ	O
significant	significant	JJ	O
results	result	NNS	O
were	be	VBD	O
found	find	VBN	O
for	for	IN	O
compounds	compound	NNS	O
bearing	bear	VBG	O
nitro	nitro	NNP	O
group	group	NN	O
.	.	.	O

The	the	DT	O
compound	compound	NN	O
5j	5j	NNP	O
and	and	CC	O
6j	6j	NN	O
with	with	IN	O
nitro	nitro	NNP	O
at	at	IN	O
para	para	NNP	O
position	position	NN	O
demonstrated	demonstrate	VBD	O
good	good	JJ	O
biological	biological	JJ	O
activity	activity	NN	O
in	in	IN	O
hippocampus	hippocampus	NNP	O
with	with	IN	O
IC50	IC50	NNP	O
=	=	SYM	O
8.68	8.68	CD	O
 	 	_SP	O
µM	µM	NNP	O
and	and	CC	O
IC50	IC50	NNP	O
=	=	SYM	O
9.32	9.32	CD	O
 	 	_SP	O
µM	µM	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
compound	compound	NN	O
5i	5i	CD	O
meta	meta	NNP	O
nitro	nitro	NNP	O
and	and	CC	O
6h	6h	NNP	O
ortho	ortho	NNP	O
nitro	nitro	NNP	O
displayed	display	VBD	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
in	in	IN	O
cerebral	cerebral	JJ	O
cortex	cortex	NN	O
with	with	IN	O
IC50	IC50	NNP	O
=	=	SYM	O
10.25	10.25	CD	O
 	 	_SP	O
µM	µM	NNP	O
and	and	CC	O
IC50	IC50	NNP	O
=	=	SYM	O
11.03	11.03	CD	O
 	 	_SP	O
µM	µM	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

IC50	IC50	NNP	O
of	of	IN	O
AChE	AChE	``	O
inhibition	inhibition	NN	O
for	for	IN	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
5	5	CD	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6	6	CD	O
.	.	.	O

nd	nd	NNP	O
not	not	RB	O
determinated	determinate	VBN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
present	present	JJ	O
study	study	NN	O
,	,	,	O
we	-PRON-	PRP	O
evaluated	evaluate	VBD	O
in	in	IN	O
vitro	vitro	FW	O
the	the	DT	O
anticholinesterase	anticholinesterase	JJ	O
potential	potential	NN	O
of	of	IN	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNPS	O
from	from	IN	O
1-(2-aminoethyl)pyrrolidine	1-(2-aminoethyl)pyrrolidine	CD	O
compounds	compound	NNS	O
.	.	.	O

AChE	AChE	``	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
used	use	VBN	O
to	to	TO	O
increase	increase	VB	O
the	the	DT	O
acetylcholine	acetylcholine	NN	O
level	level	NN	O
and	and	CC	O
thus	thus	RB	O
improve	improve	VB	O
the	the	DT	O
memory	memory	NN	O
decline	decline	NN	O
in	in	IN	O
AD	AD	NNP	O
patientsCYTOWANIE	patientsCYTOWANIE	NNP	O
.	.	.	O

Investigation	investigation	NN	O
of	of	IN	O
new	new	JJ	O
anticholinesterase	anticholinesterase	NNP	O
compounds	compound	NNS	O
is	be	VBZ	O
of	of	IN	O
most	most	JJS	O
importance	importance	NN	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
fact	fact	NN	O
that	that	IN	O
:	:	:	O
i	i	NN	O
epidemiological	epidemiological	JJ	O
data	datum	NNS	O
have	have	VBP	O
shown	show	VBN	O
the	the	DT	O
increasing	increase	VBG	O
prevalence	prevalence	NN	O
of	of	IN	O
AD	ad	NN	O
worldwide	worldwide	RB	O
,	,	,	O
especially	especially	RB	O
due	due	JJ	O
to	to	IN	O
increased	increase	VBN	O
life	life	NN	O
expectancyCYTOWANIE	expectancyCYTOWANIE	NNP	O
,	,	,	B
;	;	:	O
ii	ii	LS	O
The	the	DT	O
current	current	JJ	O
drugs	drug	NNS	O
used	use	VBD	O
to	to	TO	O
treat	treat	VB	O
AD	ad	NN	O
still	still	RB	O
cause	cause	VBP	O
many	many	JJ	O
adverse	adverse	JJ	O
effects	effect	NNS	O
,	,	,	O
besides	besides	IN	O
acting	act	VBG	O
only	only	RB	O
to	to	TO	O
alleviate	alleviate	VB	O
the	the	DT	O
symptoms	symptom	NNS	O
of	of	IN	O
the	the	DT	O
disease	disease	NN	O
,	,	,	O
and	and	CC	O
therefore	therefore	RB	O
a	a	DT	O
palliative	palliative	JJ	O
alternative	alternative	NN	O
therapy	therapy	NN	O
besides	besides	IN	O
that	that	DT	O
presents	present	VBZ	O
limitation	limitation	NN	O
of	of	IN	O
loss	loss	NN	O
of	of	IN	O
therapeutic	therapeutic	JJ	O
efficacy	efficacy	NN	O
with	with	IN	O
timeCYTOWANIE	timeCYTOWANIE	NNP	O
,	,	,	B
.	.	.	O

In	in	IN	O
this	this	DT	O
sense	sense	NN	O
,	,	,	O
is	be	VBZ	O
very	very	RB	O
important	important	JJ	O
the	the	DT	O
search	search	NN	O
for	for	IN	O
new	new	JJ	O
possible	possible	JJ	O
therapeutic	therapeutic	JJ	O
compounds	compound	NNS	O
.	.	.	O

The	the	DT	O
use	use	NN	O
of	of	IN	O
AChE	AChE	``	O
from	from	IN	O
rodents	rodent	NNS	O
,	,	,	O
especially	especially	RB	O
rats	rat	NNS	O
,	,	,	O
to	to	TO	O
screen	screen	VB	O
for	for	IN	O
new	new	JJ	O
compounds	compound	NNS	O
with	with	IN	O
possible	possible	JJ	O
anticholinesterase	anticholinesterase	NN	O
activity	activity	NN	O
is	be	VBZ	O
widely	widely	RB	O
used	use	VBN	O
.	.	.	O

Possibly	possibly	RB	O
this	this	DT	O
is	be	VBZ	O
due	due	JJ	O
to	to	IN	O
the	the	DT	O
very	very	RB	O
high	high	JJ	O
functional	functional	JJ	O
and	and	CC	O
structural	structural	JJ	O
similarity	similarity	NN	O
of	of	IN	O
AChE	AChE	``	O
from	from	IN	O
different	different	JJ	O
species	specie	NNS	O
including	include	VBG	O
human-	human-	NN	O
and	and	CC	O
rat	rat	NN	O
AChE.	ache.	NN	O
This	this	DT	O
similarity	similarity	NN	O
is	be	VBZ	O
partly	partly	RB	O
due	due	JJ	O
to	to	IN	O
the	the	DT	O
equality	equality	NN	O
found	find	VBN	O
in	in	IN	O
the	the	DT	O
primary	primary	JJ	O
and	and	CC	O
tertiary	tertiary	JJ	O
structure	structure	NN	O
of	of	IN	O
AChECYTOWANIE	AChECYTOWANIE	NNP	O
,	,	,	B
.	.	.	O

Wiesner	Wiesner	NNP	O
et	et	FW	O
 	  	_SP	O
al	al	NNP	O
.	.	.	B
also	also	RB	O
reported	report	VBD	O
that	that	IN	O
Rattus	Rattus	NNP	O
norvegicus	norvegicus	NN	O
AChEs	aches	DT	O
structures	structure	NNS	O
must	must	MD	O
be	be	VB	O
very	very	RB	O
similar	similar	JJ	O
to	to	IN	O
human	human	JJ	O
structure	structure	NN	O
and	and	CC	O
have	have	VBP	O
properties	property	NNS	O
identical	identical	JJ	O
to	to	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
.	.	.	O

Also	also	RB	O
,	,	,	O
although	although	IN	O
some	some	DT	O
studies	study	NNS	O
use	use	VBP	O
the	the	DT	O
isolated	isolated	JJ	O
form	form	NN	O
of	of	IN	O
AChE	AChE	``	O
,	,	,	O
the	the	DT	O
use	use	NN	O
of	of	IN	O
crude	crude	NN	O
homogenised	homogenise	VBN	O
from	from	IN	O
rat	rat	NN	O
’s	’s	POS	O
brain	brain	NN	O
structures	structure	NNS	O
,	,	,	O
as	as	IN	O
used	use	VBN	O
in	in	IN	O
the	the	DT	O
present	present	JJ	O
work	work	NN	O
,	,	,	O
is	be	VBZ	O
widely	widely	RB	O
used	use	VBN	O
and	and	CC	O
proves	prove	VBZ	O
to	to	TO	O
be	be	VB	O
an	an	DT	O
important	important	JJ	O
source	source	NN	O
of	of	IN	O
AChE	AChE	``	O
for	for	IN	O
in	in	FW	O
vitro	vitro	FW	O
studiesCYTOWANIE	studiescytowanie	FW	O
.	.	.	O

Here	here	RB	O
we	-PRON-	PRP	O
determinate	determinate	VBP	O
the	the	DT	O
in	in	FW	O
vitro	vitro	FW	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
5	5	CD	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6	6	CD	O
against	against	IN	O
AChE	AChE	``	O
enzyme	enzyme	NNS	O
inhibition	inhibition	NN	O
activity	activity	NN	O
in	in	IN	O
hippocampus	hippocampus	NNP	O
and	and	CC	O
cerebral	cerebral	JJ	O
cortex	cortex	NN	O
of	of	IN	O
rats	rat	NNS	O
.	.	.	O

First	first	RB	O
,	,	,	O
compounds	compound	NNS	O
with	with	IN	O
different	different	JJ	O
substituents	substituent	NNS	O
at	at	IN	O
para	para	NNP	O
position	position	NN	O
of	of	IN	O
aryl	aryl	NNP	O
ring	re	VBG	O
with	with	IN	O
electron	electron	NN	O
-	-	HYPH	O
withdrawing	withdrawing	NN	O
F	F	NNP	O
,	,	,	O
Cl	Cl	NNP	O
,	,	,	O
NO2	NO2	NNP	O
and	and	CC	O
electron	electron	NN	O
-	-	HYPH	O
donating	donate	VBG	O
groups	group	NNS	O
CH3	CH3	NNP	O
,	,	,	O
OH	oh	UH	O
,	,	,	O
OCH3	OCH3	NNP	O
were	be	VBD	O
used	use	VBN	O
Figures	figure	NNS	O
2	2	CD	O
,	,	,	O
3	3	CD	O
,	,	,	O
S132	S132	NNP	O
and	and	CC	O
S133	S133	NNP	O
.	.	.	O

The	the	DT	O
best	good	JJS	O
results	result	NNS	O
were	be	VBD	O
found	find	VBN	O
for	for	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
5j	5j	NNP	O
–	–	:	O
NO2	NO2	NNP	O
and	and	CC	O
for	for	IN	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6a	6a	NNP	O
–	–	:	O
H	h	NN	O
,	,	,	O
6j	6j	NN	O
–	–	:	O
NO2	NO2	NNP	O
,	,	,	O
6k	6k	CD	O
–	–	:	O
CH3	CH3	NNP	O
and	and	CC	O
6n	6n	NNP	O
–	–	:	O
OCH3	OCH3	NNP	O
.	.	.	O

Once	once	IN	O
the	the	DT	O
best	good	JJS	O
results	result	NNS	O
were	be	VBD	O
found	find	VBN	O
for	for	IN	O
compounds	compound	NNS	O
bearing	bear	VBG	O
nitro	nitro	NNP	O
and	and	CC	O
methoxy	methoxy	JJ	O
substituents	substituent	NNS	O
,	,	,	O
a	a	DT	O
selection	selection	NN	O
was	be	VBD	O
performed	perform	VBN	O
for	for	IN	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
with	with	IN	O
substituents	substituent	NNS	O
–	–	:	O
NO2	NO2	NNP	O
and	and	CC	O
for	for	IN	O
thiazinan-4-ones	thiazinan-4-one	NNS	O
with	with	IN	O
substituents	substituent	NNS	O
–	–	:	O
NO2	NO2	NNP	O
and	and	CC	O
–	–	:	O
OCH3	OCH3	NNP	O
at	at	IN	O
ortho	ortho	NNP	O
and	and	CC	O
meta	meta	JJ	O
position	position	NN	O
of	of	IN	O
aryl	aryl	NNP	O
ring	re	VBG	O
Supplementary	supplementary	JJ	O
information	information	NN	O
.	.	.	O

Analysing	analyse	VBG	O
the	the	DT	O
results	result	NNS	O
,	,	,	O
compounds	compound	VBZ	O
with	with	IN	O
nitro	nitro	NNP	O
group	group	NN	O
showed	show	VBD	O
AChE	AChE	``	O
inhibition	inhibition	NN	O
activity	activity	NN	O
for	for	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
5i	5i	NNP	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6h	6h	NNP	O
and	and	CC	O
6i	6i	NN	O
and	and	CC	O
compounds	compound	NNS	O
with	with	IN	O
methoxy	methoxy	JJ	O
group	group	NN	O
showed	show	VBD	O
AChE	AChE	``	O
inhibition	inhibition	NN	O
activity	activity	NN	O
for	for	IN	O
thiazinan-4-one	thiazinan-4-one	NNP	O
6l	6l	IN	O
and	and	CC	O
6	6	CD	O
m	m	NN	O
.	.	.	O

Between	between	IN	O
the	the	DT	O
two	two	CD	O
heterocycles	heterocycle	NNS	O
tested	test	VBN	O
,	,	,	O
the	the	DT	O
six	six	CD	O
-	-	HYPH	O
membered	membere	VBN	O
thiazinan-4-one	thiazinan-4-one	NNP	O
showed	show	VBD	O
more	more	JJR	O
compounds	compound	NNS	O
6a	6a	NNP	O
,	,	,	O
6h	6h	CD	O
,	,	,	O
6j	6j	NNP	O
,	,	,	O
6k	6k	CD	O
and	and	CC	O
6n	6n	CD	O
with	with	IN	O
good	good	JJ	O
AChE	AChE	''	O
inhibitory	inhibitory	NN	O
.	.	.	O

The	the	DT	O
position	position	NN	O
of	of	IN	O
substituent	substituent	NN	O
on	on	IN	O
the	the	DT	O
aryl	aryl	NNP	O
ring	ring	NN	O
did	do	VBD	O
not	not	RB	O
show	show	VB	O
significant	significant	JJ	O
difference	difference	NN	O
for	for	IN	O
the	the	DT	O
biological	biological	JJ	O
activity	activity	NN	O
with	with	IN	O
a	a	DT	O
small	small	JJ	O
preference	preference	NN	O
for	for	IN	O
the	the	DT	O
para	para	NN	O
substitution	substitution	NN	O
.	.	.	O

Disubstituted	disubstitute	VBN	O
aryl	aryl	NNP	O
reduced	reduce	VBD	O
the	the	DT	O
activity	activity	NN	O
.	.	.	O

Compounds	compound	VBZ	O
6a	6a	NNP	O
H	H	NNP	O
and	and	CC	O
6k	6k	CD	O
4-CH3	4-ch3	CD	O
showed	show	VBD	O
the	the	DT	O
best	good	JJS	O
results	result	NNS	O
in	in	IN	O
biological	biological	JJ	O
activity	activity	NN	O
inhibition	inhibition	NN	O
of	of	IN	O
AChE	AChE	``	O
in	in	IN	O
cerebral	cerebral	JJ	O
cortex	cortex	NNP	O
and	and	CC	O
hippocampus	hippocampus	NNP	O
with	with	IN	O
the	the	DT	O
lowest	low	JJS	O
IC50	IC50	NNP	O
values	value	NNS	O
,	,	,	O
suggesting	suggest	VBG	O
that	that	IN	O
a	a	DT	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
acceptor	acceptor	NN	O
HBA	HBA	NNP	O
is	be	VBZ	O
not	not	RB	O
required	require	VBN	O
on	on	IN	O
the	the	DT	O
aryl	aryl	NNP	O
ring	ring	NN	O
.	.	.	O

Plus	plus	CC	O
,	,	,	O
electronic	electronic	JJ	O
effects	effect	NNS	O
also	also	RB	O
do	do	VBP	O
not	not	RB	O
are	are	VB	O
important	important	JJ	O
for	for	IN	O
activity	activity	NN	O
once	once	RB	O
a	a	DT	O
neutral	neutral	JJ	O
methyl	methyl	NN	O
group	group	NN	O
or	or	CC	O
unsubstituted	unsubstituted	JJ	O
aryl	aryl	NNP	O
showed	show	VBD	O
the	the	DT	O
best	good	JJS	O
results	result	NNS	O
.	.	.	O

Previous	previous	JJ	O
studies	study	NNS	O
also	also	RB	O
have	have	VBP	O
evaluated	evaluate	VBN	O
the	the	DT	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
others	other	NNS	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
compounds	compound	VBZ	O
on	on	IN	O
AChE	AChE	``	O
activity	activity	NN	O
.	.	.	O

Özadalı	Özadalı	NNP	O
et	et	NNP	O
 	  	_SP	O
al	al	NNP	O
.	.	NNP	B
report	report	VBP	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
derived	derive	VBN	O
from	from	IN	O
different	different	JJ	O
heterocyclic	heterocyclic	NN	O
and	and	CC	O
showed	show	VBD	O
that	that	IN	O
these	these	DT	O
compounds	compound	NNS	O
have	have	VBP	O
higher	high	JJR	O
antihistamine	antihistamine	NN	O
activity	activity	NN	O
but	but	CC	O
not	not	RB	O
anticholinergic	anticholinergic	JJ	O
action	action	NN	O
.	.	.	O

Other	other	JJ	O
studies	study	NNS	O
have	have	VBP	O
reported	report	VBN	O
that	that	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
pyrrolidine	pyrrolidine	NNP	O
heterocycle	heterocycle	NNP	O
in	in	IN	O
the	the	DT	O
synthesised	synthesise	VBN	O
products	product	NNS	O
showed	show	VBD	O
a	a	DT	O
potential	potential	JJ	O
inhibitory	inhibitory	JJ	O
effect	effect	NN	O
of	of	IN	O
AChECYTOWANIE	AChECYTOWANIE	NNP	O
,	,	,	B
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
previous	previous	JJ	O
research	research	NN	O
from	from	IN	O
our	-PRON-	PRP$	O
research	research	NN	O
group	group	NN	O
has	have	VBZ	O
demonstrated	demonstrate	VBN	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
benzothiazinan-4-one	benzothiazinan-4-one	NNP	O
and	and	CC	O
the	the	DT	O
potential	potential	NN	O
of	of	IN	O
some	some	DT	O
compounds	compound	NNS	O
in	in	IN	O
inhibited	inhibit	VBN	O
the	the	DT	O
AChE	AChE	NNP	O
activity	activity	NN	O
from	from	IN	O
hippocampus	hippocampus	NNP	O
and	and	CC	O
cerebral	cerebral	JJ	O
cortex	cortex	NN	O
from	from	IN	O
rats	rat	NNS	O
,	,	,	O
demonstrating	demonstrate	VBG	O
the	the	DT	O
importance	importance	NN	O
of	of	IN	O
this	this	DT	O
heterocycle	heterocycle	NN	O
in	in	IN	O
the	the	DT	O
cholinergic	cholinergic	NNP	O
actionCYTOWANIE	actionCYTOWANIE	NNP	O
.	.	.	O

Comparing	compare	VBG	O
these	these	DT	O
reports	report	NNS	O
with	with	IN	O
the	the	DT	O
study	study	NN	O
proposed	propose	VBN	O
in	in	IN	O
this	this	DT	O
paper	paper	NN	O
,	,	,	O
I	-PRON-	PRP	O
point	point	VBP	O
out	out	RP	O
that	that	IN	O
the	the	DT	O
union	union	NN	O
of	of	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
and	and	CC	O
thiazinan-4-one	thiazinan-4-one	NNP	O
with	with	IN	O
pyrrolidine	pyrrolidine	JJ	O
heterocycle	heterocycle	NNP	O
aimed	aim	VBN	O
at	at	IN	O
enhancing	enhance	VBG	O
AChE	AChE	``	O
inhibition	inhibition	NN	O
activity	activity	NN	O
,	,	,	O
as	as	RB	O
indeed	indeed	RB	O
observed	observe	VBN	O
with	with	IN	O
the	the	DT	O
results	result	NNS	O
found	find	VBN	O
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
important	important	JJ	O
to	to	TO	O
empathise	empathise	VB	O
that	that	IN	O
the	the	DT	O
compounds	compound	NNS	O
5j	5j	NNP	O
,	,	,	O
6a	6a	NNP	O
,	,	,	O
6h	6h	CD	O
,	,	,	O
6j	6j	NNP	O
,	,	,	O
6k	6k	CD	O
and	and	CC	O
6n	6n	NNP	O
did	do	VBD	O
not	not	RB	O
change	change	VB	O
de	de	IN	O
cell	cell	NN	O
viability	viability	NN	O
of	of	IN	O
astrocytes	astrocyte	NNS	O
,	,	,	O
which	which	WDT	O
is	be	VBZ	O
an	an	DT	O
important	important	JJ	O
cell	cell	NN	O
of	of	IN	O
the	the	DT	O
central	central	JJ	O
nervous	nervous	JJ	O
system	system	NN	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
these	these	DT	O
compounds	compound	NNS	O
become	become	VBP	O
important	important	JJ	O
study	study	NN	O
targets	target	NNS	O
,	,	,	O
since	since	IN	O
besides	besides	IN	O
presenting	present	VBG	O
a	a	DT	O
potent	potent	JJ	O
AChE	AChE	``	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
,	,	,	O
they	-PRON-	PRP	O
did	do	VBD	O
not	not	RB	O
show	show	VB	O
toxicity	toxicity	NN	O
from	from	IN	O
brain	brain	NN	O
healthy	healthy	JJ	O
cells	cell	NNS	O
.	.	.	O

In	in	IN	O
conclusion	conclusion	NN	O
,	,	,	O
two	two	CD	O
series	series	NN	O
of	of	IN	O
thiazolidin-4-ones	thiazolidin-4-ones	NNP	O
and	and	CC	O
thiazinan-4-ones	thiazinan-4-ones	NNPS	O
derived	derive	VBD	O
from	from	IN	O
1-(2-aminoethyl)pyrrolidine	1-(2-aminoethyl)pyrrolidine	CD	O
were	be	VBD	O
efficient	efficient	JJ	O
synthesised	synthesise	VBN	O
in	in	IN	O
moderate	moderate	JJ	O
to	to	IN	O
good	good	JJ	O
yields	yield	NNS	O
.	.	.	O

Tests	test	NNS	O
for	for	IN	O
AChE	AChE	``	O
inhibition	inhibition	NN	O
activity	activity	NN	O
showed	show	VBD	O
potent	potent	JJ	O
biological	biological	JJ	O
activity	activity	NN	O
for	for	IN	O
thiazolidin-4-one	thiazolidin-4-one	NNP	O
5j	5j	NNP	O
and	and	CC	O
thiazinan-4-one	thiazinan-4-one	NNP	O
6a	6a	NNP	O
,	,	,	O
6h	6h	CD	O
,	,	,	O
6j	6j	NNP	O
,	,	,	O
6k	6k	CD	O
and	and	CC	O
6n	6n	CD	O
,	,	,	O
highlighted	highlight	VBN	O
by	by	IN	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
6a	6a	NNP	O
and	and	CC	O
6k	6k	CD	O
that	that	WDT	O
show	show	VBP	O
the	the	DT	O
lowest	low	JJS	O
IC50	IC50	NNP	O
values	value	NNS	O
for	for	IN	O
hippocampus	hippocampus	NNP	O
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
also	also	RB	O
highlighted	highlight	VBN	O
that	that	IN	O
none	none	NN	O
of	of	IN	O
tested	test	VBN	O
compounds	compound	NNS	O
showed	show	VBD	O
cytotoxic	cytotoxic	NN	O
when	when	WRB	O
evaluated	evaluate	VBN	O
in	in	IN	O
the	the	DT	O
cellular	cellular	JJ	O
viability	viability	NN	O
tests	test	NNS	O
of	of	IN	O
cortical	cortical	JJ	O
astrocytes	astrocyte	NNS	O
.	.	.	O

This	this	DT	O
study	study	NN	O
demonstrated	demonstrate	VBD	O
safety	safety	NN	O
for	for	IN	O
the	the	DT	O
use	use	NN	O
of	of	IN	O
thiazinan-4-ones	thiazinan-4-ones	NNP	O
for	for	IN	O
future	future	NN	O
in	in	IN	O
vivo	vivo	NNP	O
assays	assays	NNPS	O
and	and	CC	O
may	may	MD	O
be	be	VB	O
potential	potential	JJ	O
candidates	candidate	NNS	O
for	for	IN	O
the	the	DT	O
limited	limited	JJ	O
therapeutic	therapeutic	JJ	O
arsenal	arsenal	NN	O
by	by	IN	O
treatment	treatment	NN	O
of	of	IN	O
Alzheimer	Alzheimer	NNP	O
’s	’s	POS	O
disease	disease	NN	O
.	.	.	O

